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SUMMARY
Hypoxia induced periventricular white matter (PWM) damage (PWMD) is a common 
form of brain injury in preterm infants. PWMD characterized by selective loss of 
oligodendrocytes, axonal degeneration and hypomyelination results in long term 
neurological consequences such as mental retardation, cerebral palsy, epilepsy, visual 
and hearing loss. Among various factors that have been proposed to mediate the 
pathogenesis of PWMD, excess iron which is known to result in tissue injury through 
free radical mediated mechanism, has received less attention. Based on this, the present 
study was undertaken to identify the molecular mechanisms involved in iron 
accumulation in hypoxic PWM and to elucidate the pathways through which iron could 
mediate the death of oligodendrocytes, a hallmark feature of PWMD.  
Owing to the similarity in the white matter development in midgestation human 
foetuses, one day old wistar rats were used to elucidate the role of iron in hypoxic 
PWMD. Hypoxic conditioning resulted in drastic increase in iron levels in the PWM 
and this was accompanied by the enhanced expression of proteins involved in iron 
regulation such as hypoxia inducible factor-1α (HIF-1α) and iron regulatory proteins 
(IRPs: IRP1 and IRP2), leading to dysregulation of iron levels in hypoxic PWM. In 
addition, the expression of proteins involved in iron transport such as transferrin 
receptor (TfR), divalent metal transporter-1(DMT1), ferroportin (FPN1) and 
ceruloplasmin (CP) was increased.  Double immunofluorescence revealed the 
differential expression of these proteins in the microglia, astrocytes, oligodendrocytes 
and the blood vessels. Perls’ iron staining revealed the localization of iron in the 
amoeboid microglial cells (AMCs), indicating the capability of these cells to sequester 
excess iron in the hypoxic PWM.  
Elucidation of the iron accumulation pathway in the hypoxic microglial cultures 
indicated that the up-regulation of HIF-1α, IRP1 and IRP2, accounted for the increased 
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expression of iron uptake proteins TfR and DMT1 in cultured microglial cells in 
response to hypoxia.  Although activated microglia are known to produce cytokines and 
free radicals, the use of deferoxamine, an iron chelator, in this study suggested that the 
production of reactive oxygen species (ROS) and pro-inflammatory cytokines tumor 
necrosis factor (TNF)-α and interleukin (IL)-1β, was mediated by excess iron 
accumulated in hypoxic microglial cultures.  Treating the primary oligodendrocytes 
with conditioned medium derived from hypoxic microglial cells, containing ROS, TNF-
α and IL-1β, resulted in reduced glutathione content, increased lipid peroxidation, 
increased caspase-3 labelling and reduced proliferation in oligodendrocytes. However, 
these changes were reversed to control levels in oligodendrocytes treated with medium 
derived from deferoxamine treated hypoxic microglial cultures. The incidence of 
apoptosis, which was high when the oligodendrocytes were treated with medium from 
hypoxic microglia, was reduced when subjected to treatment with medium derived from 
deferoxamine treated hypoxic microglia.  Taken together, these results suggest that the 
increased iron accumulated within hypoxic microglia could result in enhanced release of 
ROS and cytokines and lead to death of oligodendrocytes. 
 Besides the above, in response to hypoxia, the AMCs of developing PWM showed 
enhanced expression of matrix metalloproteinase (MMP)-9, which is implicated in 
disrupting the blood brain barrier (BBB). In hypoxic neonatal rats administered with 
deferoxamine, the expression of MMP-9 in AMCs was reduced suggesting the role of 
iron in causing BBB disruption in hypoxic PWMD.  
Further analysis to reveal the mechanism by which deferoxamine attenuated excess 
cytokine production showed a differential regulation in the expression of mitogen 
activated protein kinases (MAPKs) in hypoxic microglia. Deferoxamine treatment 
resulted in increased extracellular signal-regulated kinase phosphorylation (p-ERK) 
xix 
with a simultaneous down regulation of phosphorylation of P38 (p-P38) which is well 
known to evoke inflammatory mediator production in hypoxic microglia. The increased 
p-ERK resulted in the activation of cAMP response element binding protein through 
phosphorylation (p-CREB). This increase in p-CREB was accompanied by MAPK 
phosphatase-1 (MKP1) up-regulation in deferoxamine treated hypoxic microglia 
suggesting an association between p-ERK induced p-CREB in MKP-1 production. The 
increased MKP-1 dephosphorylates p-P38 and thereby attenuates the production of 
cytokines in hypoxic microglia when treated with deferoxamine. 
In addition to microglia, the possibility that the increase in iron concentrations within 
hypoxic oligodendrocytes could contribute to their death was evaluated. Increased 
expression of HIF-1α, IRP1 and IRP2 was also localised in the oligodendrocytes of 
hypoxic PWM. The increased accumulation of iron evoked endoplasmic reticulum (ER) 
stress response by eliciting ryanodine receptor (RyR) activation, in hypoxic 
oligodendrocytes. The increase in Binding immunoglobulin protein (BiP) and inositol-
requiring enzyme (IRE)-1α in hypoxic oligodendrocytes and the decreased expression 
of protein kinase RNA-like endoplasmic reticulum kinase (PERK) was attributed to the 
misfolded protein response of ER resulting in ER stress.  In hypoxic oligodendrocytes 
treated with deferoxamine the expression levels of BIP, IRE-1α and PERK was 
comparable to that of control levels. Further ER stress induced p53 activation was also 
attenuated on treatment with deferoxamine suggesting a reduced oligodendrocyte 
apoptosis. Hence, the present study emphasizes that the excess accumulation of iron in 
PWM, in response to hypoxia, could lead to PWMD, by mediating mechanism that 
could either directly or indirectly lead to death of oligodendrocytes.   
xx 
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Periventricular white matter (PWM) damage (PWMD), also known as the 
periventricular leukomalacia (PVL) remains as the predominant cause of morbidity in 
premature infants (Volpe, 2000; Back and Rivkees, 2004; Ferriero, 2004; Back, 2006). 
Though advancements in neonatal intensive care have increased the survival rates of 
premature infants (Volpe, 2001), the number of premature infants suffering long-term 
neurological impairments has not decreased significantly (Wilson-Costello et al., 2005). 
PWMD is particularly evident in premature infants born between 23 and 37 weeks of 
gestation and with low birth weight <1500g (Johnston, 1997; Rezaie and Dean, 2002; 
Volpe, 2003; Follett et al., 2004; McQuillen and Ferriero, 2004; Folkerth, 2006).  
Various factors such as infection, inflammation, vascular factors, hypoxia, pre-
eclampsia, and genetic factors have been suggested to predispose the immature brains to 
PWMD. Clinical and experimental studies have pointed to reduced supply of oxygen to 
the brain or hypoxia as the major contributing factor for PWMD in premature neonates 
(Baud et al., 2004b; Alvarez-Diaz et al., 2007; Huang and Castillo, 2008). Prenatal 
hypoxia may occur due to various maternal causes such as anemia, asthma, diabetes, 
smoking, cardiac dysfunctions, alcohol or drug abuse and multiple gestational 
pregnancies (Baud et al., 2004b; Golan et al., 2004). Furthermore, decreased utero-
placental blood flow, intra-uterine infection and prolonged labor may compromise the 
oxygen supply to the fetus (Takashima and Tanaka, 1978; Dammann and Leviton, 1997; 
Froen et al., 2002; Golan et al., 2004).  
PWMD is composed of either a focal necrotic component: characterized by 




component: characterized by reactive microglia and astrocytes and associated injury to 
the glial cell (Volpe, 2003), particularly the oligodendrocytes (Deng et al., 2008). Lack 
of anastomoses and extensive occurrence of  premyelinating oligodendrocytes render 
the PWM highly vulnerable to hypoxic insult (Folkerth, 2006). Damage to the 
oligodendrocytes results in delayed or disrupted myelination (Huang et al., 2009; 
Tzarouchi et al., 2009) leading to neurodevelopmental deficits such as cerebral palsy, 
mental retardation, impaired vision, cognitive deficits and hearing impairments (Inder et 
al., 2003; Back and Rivkees, 2004; Iwata et al., 2004; Nosarti et al., 2004; Vannucci and 
Vannucci, 2005). Besides the above, the pathological events in hypoxic PWMD include 
axonal swelling (Volpe, 2009), astrogliosis and activation of microglia.     
Lack of antioxidant such as glutathione in the developing oligodendrocytes has 
been reported to be the foremost mediator of PWMD. Additionally, several factors such 
as glutamate toxicity (Volpe, 2001), reduced cerebral blood flow autoregulation (Berger 
et al., 2002), release of inflammatory cytokines, vascular factors (Kaur et al., 2006b), 
impaired intracellular calcium turnover, accumulation of iron (Adcock et al., 1996; 
Palmer et al., 1999) and overproduction of free-radicals (Amato and Donati, 2000) have 
been proposed to mediate the pathogenesis of PWMD. In the PWM of developing brain, 
the above mentioned factors have been reported to be produced by the activated 
microglia and astrocytes, in response to hypoxia (Haynes et al., 2003; Volpe, 2003; 
Kaur et al., 2006b; Sivakumar et al., 2010; Murugan et al., 2011). Activated glia and 
their response to hypoxia are thought to play an important role in damaging axons and 




1.1 Composition of periventricular white matter 
The PWM region (shown in figure I) located peripheral to the lateral ventricles 
is composed of the glial cells (microglia, astrocytes and oligodendrocytes), axons, and 
the blood vessels (Filley, 2005). 
1.1.1 Microglia 
Microglia, first described by del Rio Hortega, are the resident macrophages of 
the brain. They constitute nearly 10-15% of the brain glial cells and are preponderant in 
the developing PWM (Ling and Wong, 1993). Origin of microglia has been a topic of 
debate in the scientific community for a long time. The most widely accepted theory is 
of hematopoietic origin of microglia (Ling et al., 1991; Kaur et al., 2001). During the 
periods of early development of brain the microglial precursors in the blood stream 
invade the developing brain (Imamoto and Leblond, 1978; Ling et al., 1980) and 
increase in numbers in the central nervous system (CNS). Markers of monocytes such as 
ED-1, OX-42, F4/80, lectin (Griffonia simplicifolia) were used to study the appearance 
and distribution of microglia in the brain. In the developing PWM, the amoeboid 
phenotype of microglia is preponderant. Amoeboid microglial cells (AMCs) have been 
implicated in rebuilding the histo-architecture of white matter during development by 
involving in phagocytosis of cellular debris/apoptotic cells, synaptic pruning and 
myelination. As the development proceeds, AMCs transform themselves into the highly 
ramified resting form of microglia called the ramified microglia cells. Microglia, being 
highly sensitive to changes in the micro-environment of brain, become activated under 
pathological conditions and may result in damage to oligodendrocytes. AMCs activated 




cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, nitric oxide 
(NO) and free radicals (Deng et al., 2008; Kaur et al., 2009; Sivakumar et al., 2010; 
Murugan et al., 2011) which could result in the death of oligodendrocytes.  In addition, 
under pathological conditions, AMCs have been demonstrated to express major 
histocompatibility class II (MHCII) antigens (Kaur et al., 2004). Expression of MHCII 
on AMCs indicates that these cells could initiate the immune responses by interacting 
with T helper cells (Kaur et al., 2004; Kaur et al., 2007) disrupting the immune privilege 
environment of the brain.  
 
                              
Figure I: Light microscopic image of coronal section of rat brain stained with neutral 
red showing the periventricular white matter (PWM) and lateral ventricles (V)   
 
1.1.2 Astrocytes 
Astrocytes are star shaped glial cells originating from the ventricular zone. They 







integrity and glutamate homeostasis (Anderson and Swanson, 2000; Abbott, 2002; 
Simard and Nedergaard, 2004).  Identification of astrocytes in the brain is enabled by 
their expression of glial fibrillary acidic protein (GFAP). The astrocytes with thin long 
processes called the fibrous astrocytes predominate the PWM (Miller and Raff, 1984). 
In the developing brain, astrocytes are involved in the formation of molecular 
boundaries, which is essential for guiding the extension of developing axons and 
migration of neuroblasts (Powell and Geller, 1999). The connections established by 
astrocytes with other glial cells, by means of gap junctions and connexins, ensure proper 
myelination process (Lutz et al., 2009). In response to an injury, the astrocytes become 
reactive exhibiting features such as cellular hyperplasia, hypertrophy, increased 
expression GFAP (Zhu et al., 2004), swelling of end-feet enveloping BBB and 
increased proliferation (Sullivan et al., 2010).  Reactive astrocytes are actively involved 
in the formation of glial scars which could inhibit axonal regeneration and recovery 
following injury (Di Giovanni et al., 2005). Prolonged astrocytosis could also lead to 
release of cytokines like microglia that are toxic to oligodendrocytes (Deng et al., 2010).  
1.1.3 Oligodendrocytes  
Oligodendrocytes are the myelin forming cells in the CNS, originating from the 
neuroepithelial cells of the ventricular zone during early embryonic life (Thomas et al., 
2000). The germinal matrix of subventricular zone is also considered to be a source for 
oligodendrocytes (Luskin et al., 1988; Levison and Goldman, 1993). The 
oligodendrocyte progenitors then migrate to different regions of the developing brain, 
especially to the regions of future white matter were they myelinate the axons 




reaching the regions of future white matter settle along the axonal tracts and 
differentiate into myelin producing mature oligodendrocytes. In the process of 
myelination, the oligodendrocytes extend their processes to contact the axons and to 
ensheath them repeatedly, which later condenses to form the multispiral myelin sheath 
(Baumann and Pham-Dinh, 2001). In the course of development, the oligodendrocytes 
are identified by their ability to express phenotypically different markers during 
development. Based on this, they are classified into early oligodendrocyte progenitors 
(A2B5+), late oligodendrocyte progenitors (PDGFα+, O4+, NG2+), immature 
oligodendrocytes (CC1+, O1+) and mature oligodendrocytes (MBP+). During the high 
risky periods of PWMD it is the pre-myelinating oligodendrocytes which dominate the 
white matter (Kinney and Back, 1998; Pang et al., 2000). Since pre-myelinating 
oligodendrocyte lack certain antioxidant enzymes when compared to mature 
oligodendrocytes, they are highly vulnerable to hypoxic damage (Mitrovic et al., 1994; 
Kinney and Back, 1998; Folkerth et al., 2004). In addition, oligodendrocytes also 
express receptors for cytokines such as interferon γ (IFNγ), TNF-α and IL-1β (Folkerth 
et al., 2004; Deng et al., 2008) and for glutamate (Talos et al., 2006; Murugan et al., 
2011).  Hence, damage to the developing oligodendrocytes may also occur via 
inflammatory mediators and glutamate induced excitotoxicity. As the axons of 
developing PWM are unmyelinated, damage to oligodendrocytes could result in 
hypomyelination which leads to neurological deficits.  
1.1.4 Axons 
The nerve fiber tracts traversing the PWM are the axons arising from the 




cortical regions and the two hemispheres of the brain. The axons in the PWM of 
developing brain are unmyelinated. Through the course of development, the process of 
myelination begins and the axons are wrapped by myelin sheaths that are extensions of 
the process of mature oligodendrocytes. The myelin sheath enables the saltatory 
conduction and results in faster transmission of neural signals. The myelination process 
starts during midgestation period in humans (Jakovcevski et al., 2007) whereas in 
rodents, myelination begins during the end of first week of postnatal life (Jakovcevski et 
al., 2007). Any injury to the PWM before the onset of myelination could result in 
delayed myelination or hypo-myelination leading to neurobehavioural abnormalities 
(Filley, 2005).  
1.1.5 PWM vasculature 
The PWM in a premature infant is sparsely vascularised (Miyawaki et al., 1998; 
Ballabh et al., 2005). The appearance of blood vessels in the neural tissue is reported as 
early as 7 weeks of gestation (Korzhevskii and Otellin, 2000) in humans. As the 
development proceeds, there is an increase in cerebrovascular vessel density (Ballabh et 
al., 2004b) with respect to gestational age and according to the metabolic needs. In the 
white matter, a significant increase in blood vessel density occurs after 32 weeks of 
gestation (Ballabh et al., 2004b). In addition, the endothelial cells of the cerebral blood 
vessels are glued together by the tight junctions (Balabanov and Dore-Duffy, 1998; 
Balabanov et al., 1999) forming the BBB, and play a critical role in restricting most 
blood borne elements from entering the brain. The BBB formed of endothelial cells and 
tight junctions, is supported by the astrocytes and pericytes.  The astrocytes end-feet 




et al., 2004a). The reduced blood vessel density during the period of selective 
vulnerability and the breakdown of BBB could also result in reduced cerebral blood 
flow autoregulation (Lou et al., 1978).   
1.2  Pathology of periventricular white matter damage  
In response to hypoxic-ischemic injuries, a spectrum of pathological 
consequences ranging from focal necrosis to myelination deficits is visualized in the 
PWM. The pathological hallmarks include damage to oligodendrocytes, swelling of 
axons, activation of microglia and astrocytes (Obonai and Takashima, 1998; Ness et al., 
2001; Skoff et al., 2001). The presence of apoptotic and necrotic cells in the hypoxic 
PWM is the hallmark for PWMD (Kaur and You, 2000). These apoptotic cells were 
found to be oligodendrocytes by labelling with CC1 (a marker for oligodendrocytes) 
(Deng et al., 2008).  In addition, glioblasts known to be oligodendrocyte precursors 
displayed ballooning of nuclear envelope associated with splitting of inner and outer 
nuclear membrane (Kaur and Ling 2009). Oligodendrocytes are well-known to be 
actively involved in the myelination of axons in the developing brain. Oligodendrocyte 
precursors are known to dominate the PWM during 23-32 weeks of gestation in human 
(Pang et al., 2000). Therefore, a hypoxic-ischemic injury during this gestational period, 
which causes apoptosis of oligodendrocytes, results in delayed/disrupted myelin 
formation leading to severe neurobehavioral anomalies that last through childhood and 
adulthood (Volpe, 2003). In accordance with this, decreased myelin basic protein 
(MBP) expression has been demonstrated in hypoxic-ischemic PWM (Liu et al., 2002; 




of PWM injury are usually accompanied by impaired or delayed myelination 
(Kurumatani et al., 1998; Jelinski et al., 1999; Cai et al., 2001). 
Along with the apoptotic oligodendrocytes, the axons were found to be swollen 
and degenerating (Kaur et al., 2006b). In neonatal brains, in response to hypoxia, the 
number of degenerating axons was reported to be enhanced (Kaur et al., 2006b). 
Associated with this, the damaged axons were found to be deficient in axoplasm and, if 
myelinated, had distorted myelin sheath (Kaur et al., 2006b). Recent studies reported 
that the contacts between axons and oligodendrocyte precursor cells, in the white matter 
of developing rats, were profoundly damaged following hypoxic-ischemic insults (Shen 
et al., 2012). 
The presence of activated microglia has been detected in the PWM of children 
with signs of PVL (Deguchi et al., 1996; Kadhim et al., 2001; Haynes et al., 2003) and 
in asphyxiated animal foetuses (Mallard et al., 2003).  As microglial cells are 
preponderant in the developing PWM (Billiards et al., 2006), their activation is 
implicated in the pathogenesis of PWMD. Activation of microglia induces the 
production of a repertoire of cytotoxic factors in microglia, which are implicated in 
oligodendrocyte death. In hypoxic PWM, the activated microglia were found to actively 
phagocytose the apoptotic and necrotic cells and the degenerating axons (Kaur and 
Ling, 2009).  
Cerebral white matter astrocytosis is another characteristic feature of PWMD 
(Hirayama et al., 2001). Though astrocytosis could favour in the repair of PWM, 




and Kaminska, 2003), either by producing pro-inflammatory cytokines (Deng et al., 
2010) or by inhibiting axonal re-growth (Di Giovanni et al., 2005). Vascular endothelial 
growth factor (VEGF), an angiogenic growth factor produced by astrocytes is not only 
known to induce vasculogenesis but also reported to enhance the vascular permeability 
(Croll et al., 2004). Ment et al (1997) demonstrated the increased expression of VEGF 
in astrocytes in white matter at the vicinity of foci of necrosis. Following hypoxic insult, 
the up-regulation of VEGF expression in astrocytes in PWM was suggested to have a 
critical role in edema formation by enhancing vascular leakage (Kaur et al., 2006b). 
PWMD is further contributed by factors such as circulatory disturbances, edema, 
and haemorrhage, which could lead to subsequent necrosis of the cells in the PWM 
(Nakamura et al., 1994). PWMD is often accompanied by germinal matrix hemorrhage 
(Folkerth, 2005) and intraventricular hemorrhage (Okoshi et al., 2001). In response to 
hypoxic insults, vacuoles were observed in ependymal cells lining the lateral ventricles. 
Associated with this, the intercellular spaces were also widened (Kaur and Ling, 2009). 
These structural changes were speculated to favour extravasation of cerebrospinal fluid 
(CSF) into the PWM, thereby, enhancing edema formation (Kaur and Ling, 2009). 
Studies have also reported the widening of perivascular spaces and consequent edema 
formation in PWM (Sridhar et al., 2001; Kadhim et al., 2003; Kaur et al., 2006b). The 
vulnerability of PWM to hypoxic injury is attributed to the hypovascularisation of this 
region (Folkerth, 2006). 




Owing to the multifaceted nature of PWMD a complete understanding of the 
molecular mechanism leading to the damage of the PWM is still lacking. Factors such 
as impaired blood flow, increased vascular permeability, glutamate toxicity, increased 
secretion of inflammatory cytokines, excess iron accumulation and free radical 
production have been proposed to be the important mediators of PWMD. A brief 
description on the mode of their action in causing PWMD is provided here. 
1.3.1 Impaired blood flow 
Perturbations in autoregulation of blood flow to the white matter have been 
implicated in the progression of PWMD (Back et al., 2007). In the developing brain, the 
scarcely vascularised PWM (Miyawaki et al., 1998; Ballabh et al., 2005) receives a 
basal blood flow which is approximately 20 % lower than that supplied to the grey 
matter (Borch and Greisen, 1998). The PWM is supplied by long and short penetrating 
arteries (Takashima and Tanaka, 1978; Nakamura et al., 1994). The long penetrating 
arteries supplying the PWM, terminate in the deep PWM and lack vascular 
anastomoses, thereby forming a vascular end zone (Takashima and Tanaka, 1978; 
Nakamura et al., 1994) which is highly vulnerable to hypoxic damage. Besides the 
above, the blood vessel density in the PWM was found to be transiently low between 
28-36 weeks of gestation, but was increased at later gestational ages. Studies on animal 
models have estimated that the blood flow to PWM under hypoxic-ischemic conditions 
is ~ 50% less than the blood flow to the grey matter (Back et al., 2006). The reduced 
cerebral blood flow to the PWM along with other factors could lead to PWMD 




1.3.2 Increased vascular permeability 
The blood brain barrier is reported to be well established from the earliest stages 
of fetal development (Mollgard and Saunders, 1986; Saunders et al., 1991). However, 
the BBB may be disrupted by conditions such as hypoxic-ischemia or inflammation (de 
Vries et al., 1997; Abbott, 2000) resulting in increased vascular permeability. At 
molecular levels, the increase in vascular permeability could be facilitated by the 
decreased expression or disorganisation of proteins involved in the formation of tight 
junctions (Alvarez-Diaz et al., 2007). In addition, proteins such as VEGF produced by 
astrocytes and nitric oxide (NO) produced by both astrocytes and microglia could 
favour hypoxia-induced increased vascular permeability. Although VEGF is well 
known to be involved in angiogenesis, it has been reported to enhance the vascular 
permeability (Fischer et al., 1999) of the BBB. In hypoxic PWM, many VEGF positive 
astrocytes were demonstrated surrounding the blood vessels (Kaur et al., 2006b). The 
mechanism by which VEGF induces vascular leakage is not fully elucidated. However, 
it was proposed that VEGF could result in disruption or disassembly of proteins such as 
occludin and zona occludens-1 which are essential components of tight junctions (Wang 
et al., 2001). Indeed, Fischer et al (2002) have reported VEGF mediated altered 
expression of ZO-1 following hypoxia. Like VEGF, NO which is involved in 
vasodilation has been implicated in regulation of BBB permeability (Janigro et al., 
1994). Further, NO has been reported to mediate the VEGF induced vascular 
permeability (Murohara et al., 1998). Increase in VEGF and NO production has been 
observed in the PWM of neonatal rats in response to hypoxia (Kaur et al., 2006b). 




PWM, through administration of rhodamine isothiocyanate (Kaur et al., 2010). Besides 
the above, inflammatory mediators produced in response to hypoxia may also induce 
vascular leakage. Inflammatory cytokines such as IL-1, IL6 and TNF-α, have been 
reported to enhance the permeability of BBB (de Vries et al., 1996). Kim et al (1992) 
reported the presence of increased number of white blood cells in the CSF of rats 
administered with TNF-α.  The increased influx of serum derived substances into the 
PWM owing to the BBB leakage could result in tissue damage (Kaur et al., 2006b).  
1.3.3 Glutamate toxicity 
Excessive accumulation of glutamate is a common phenomenon in immature 
brains following hypoxic-ischemic insults. Both clinical and experimental studies on 
PVL have reported the same and increased glutamate levels have been suggested to 
mediate PWMD (Fern and Moller, 2000). By employing micro-dialysis, some studies 
have reported an elevated glutamate levels in the immature brains, in response to 
hypoxic insults (Benveniste et al., 1984; Silverstein et al., 1991). Additional support 
comes from clinical studies which evaluated the glutamate levels in the brains of 
perinatal infants, who suffered hypoxic-ischemia (Hagberg, 1992). Consistent with this, 
a drastic increase in glutamate levels has been reported in hypoxic PWM of neonatal 
rats (Sivakumar et al., 2010). Several sources have been proposed to contribute to the 
increased glutamate content, among them are damaged axons (Kukley et al., 2007), 
deregulation of glutamate transporters (Fern and Moller, 2000) and activated microglia 
(Sivakumar et al., 2010). Glutamate uptake by astrocytes is an energy dependent 
process and hence conditions like hypoxia which compromises oxygen consumption 




2002; Allen et al., 2004; Malarkey and Parpura, 2008). Raymond et al. (2011) 
demonstrated that astrocytic glutamate uptake was impaired in response to hypoxia in 
PWM. Excess glutamate in the hypoxic PWM, in turn, could activate the metabotropic 
and ionotropic glutamate receptors [N-methyl-D-aspartate receptors (NMDAR), alpha-
amino-3- hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kinate receptors] 
expressed on the glial cells. Administration of glutamate receptor antagonist resulted in 
alleviation of white matter damage (Follett et al., 2000; Follett et al., 2004) indicating 
that glutamate receptors are involved in oligodendrocyte death (Yoshioka et al., 1995; 
McDonald et al., 1998; Deng et al., 2003).  
The expression of AMPA, kainate and NMDA receptors on microglia and 
astrocytes has been previously demonstrated (Gottlieb and Matute, 1997; Matute et al., 
1997; Noda et al., 2000; Krebs et al., 2003). Consistent with this, in response to 
hypoxia, there was increased expression of NMDA and AMPA receptors on AMCs in 
PWM (Kaur et al., 2006a; Sivakumar et al., 2010; Murugan et al., 2011). The increased 
Ca2+ influx due to activation of these receptors has been suggested to contribute to the 
NO production and cytokine release from these glial cells (Farber and Kettenmann, 
2006).  The NO produced in response to NMDAR activation in microglial cells resulted 
in increased apoptosis of oligodendrocytes (Murugan et al., 2011). Activation of NMDA 
and AMPA receptors in AMCs and astrocytes further resulted in increased secretion of 
pro-inflammatory cytokines which are implicated in the death of oligodendrocytes 
(Sivakumar et al., 2010; Murugan et al., 2011). The increased glutamate was suggested 
to exacerbate the PWMD by supressing the release of insulin like growth factors (IGF-I 




tissue reparative process (Guan et al., 2003). IGF-I is known to protect the immature 
oligodendrocytes against glutamate mediated injury (Ness and Wood, 2002; Ness et al., 
2004). Therefore, a reduction in this growth factor in hypoxic PWM could result in 
excitotoxicity of oligodendrocytes. Besides the above, glutamate could induce VEGF 
production in astrocytes (Liu et al., 2010), which could increase the BBB permeability 
resulting in PWMD. 
1.3.4 Cytokines 
Both experimental and clinical studies have suggested that inflammation plays a 
major role in causing PWMD (Kadhim et al., 2002; Deng et al., 2008). Hypoxic insults 
trigger the production of inflammatory cytokines and chemokines (Carloni et al., 2006; 
Guo and Bhat, 2006). In the inflamed brain, microglia serve as the predominant source 
of cytokines (Hanisch et al., 2001; Kaur et al., 2007), with astrocytes being the 
secondary source. AMCs in hypoxic PWM showed enhanced expression of TNF-α and 
IL-1β (Deng et al., 2008). The production of cytokines in AMCs was facilitated by 
either the activation of mitogen activated protein kinases or by translocation of nuclear 
factor-κB into the nucleus (Deng et al., 2008; Murugan et al., 2011). Hypoxia induced 
NMDA receptor activation (Murugan et al., 2011), expression of ion channels such as 
Kv1.1 and Kv1.2, and heparan sulphate glycosaminoglycan-containing cell surface 
proteins such as syndecan-2 on hypoxic AMCs was demonstrated to promote release of 
inflammatory cytokines and chemokines (Li et al., 2008a; Kaur et al., 2009; Wu et al., 
2009). In addition, AMCs were further demonstrated to exacerbate PWMD by inducing 
cytokine production in astrocytes (Deng et al., 2010). In hypoxic PWM, the binding of 




2010) to the CSF-1R receptors expressed on astrocytes was suggested to result in 
increased production of cytokines by astrocytes (Deng et al., 2010). These results 
implied a cross talk between AMCs and astrocytes in hypoxic PWM and whose 
interaction via MCSF could aggravate the PWMD by enhancing inflammatory response 
(Deng et al., 2010).  
The inflammatory reactions are initiated when the secreted cytokines bind to 
their corresponding receptors triggering the signalling cascade. TNF-α exerts its action 
by binding to its receptors TNFR1 and TNFR2. While TNFR1 activation could elicit 
caspase mediated apoptosis (Nakazawa et al., 2006), binding to TNFR2 has been 
suggested to favour cell growth and proliferation (Fontaine et al., 2002). In hypoxic 
PWM, TNFR1 expression was localised to the oligodendrocytes and axons (Deng et al., 
2008). Thus, it could be possible that TNF-α might induce oligodendrocyte death and 
axonal degeneration in hypoxic PWM. Coupled with this, there was a reduced MBP 
expression (Deng et al., 2010) in hypoxic PWM, suggesting hypo-myelination. The 
detrimental role of IL-1β is enabled by its binding to either type I or type II IL-1 
receptors (IL-1R). In hypoxic PWM, IL-1R1 expression was found to be significantly 
increased on the oligodendrocytes (Deng et al., 2008). Though IL-1β is reported to be 
non-toxic to oligodendrocytes it could reduce the proliferation rate of late progenitor/ 
pre-oligodendrocytes (Vela et al., 2002). It is speculated that the high levels of IL-1β in 
the hypoxic PWM may impede the recovery by inhibiting the proliferation of 
oligodendrocyte progenitors. In addition, increased level of IL-1β was demonstrated to 




glutamate mediated excitotoxic mechanisms (Takahashi et al., 2003) or by initiating the 
increased production of NO (Betz et al., 1996). 
Chemokines are another set of immunoregulatory molecules secreted by 
microglia and astrocytes during inflammation.  They are small peptides (8-14 KDa) 
capable of mediating infiltration of leukocytes to the vicinity of inflammation. 
Chemokines are divided into four major families (CXC, CC, C and CX3C) based on 
their cysteine motif (Pan et al., 1997; Vaddi et al., 1997). Microglia are known to 
express chemokines such as monocyte chemoattractant protein 1 (MCP1), macrophage 
inflammatory protein-1α (MIP-1α), MIP-1β, MIP-2, CCL6 and RANTES (Cowell and 
Silverstein, 2003; Sunnemark et al., 2003; Kanno et al., 2005; Deng et al., 2009). 
Astrocytes express chemokines such as MIP-2, VEGF, stem cell factor, stromal-derived 
factor (SDF)-1α, fractalkine and MCP-1 in response to hypoxia (Xu et al., 2007). MCP-
1 is reported to promote the migration of microglia and leukocytes to the foci of lesion 
(Lu et al., 1998; Yan et al., 2007). This is enabled by the binding of MCP-1 to its 
receptor CCR2. In neonatal brains, in reposnse to hypoxia, AMCs in the PWM served 
as major source of MCP-1 (Deng et al., 2009). Coupled with this, there was an increase 
in the numbers of AMCs in the hypoxic PWM. Astrocytes derived SDF-1α, by binding 
to its receptor CXCR4 expressed on the microglial cells, favours the migration of 
microglia to the foci of lesion (Lu et al., 2009). These chemokines can also regulate 
migration of lymphocytes and monocytes to the site of damage (Cross and Woodroofe, 
1999; Ambrosini and Aloisi, 2004). Oligodendrocytes are also known to express 
chemokine receptors such as CXCR2, (Robinson et al., 1998) a receptor for CXCL1 




neutrophils. Inhibition of CXCR2 has been reported to reduce the lesion size in animal 
models of multiple sclerosis (Kerstetter et al., 2009). Hence, it is possible that binding 
of chemokines to their respective receptors expressed on oligodendrocyte may facilitate 
the death of oligodendrocytes.      
1.3.5 Nitric oxide 
Nitric oxide (NO) is released on the enzymatic conversion of L-arginine to L-
citrulline, which is catalysed by nitric oxide synthase (NOS) (Marletta, 1993). Three 
different isoforms of NOS has been identified and are referred as endothelial NOS 
(eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). NO has a wide range of 
action from being a vasodilator to potent neurotoxin and the function of NO depends on 
the source of production. NO produced by iNOS is known to be involved in immune 
modulation (Brown and Bal-Price, 2003).  In the developing PWM, expression of iNOS 
is hardly detected, whereas when subjected to hypoxia, its expression was increased 
(Kaur et al., 2006b). The expression of iNOS was localized in the activated microglial 
cells in the hypoxic PWM (You and Kaur, 2000). Activated microglial cells expressing 
iNOS have been proposed to be the major source of NO under pathological conditions 
(Murphy et al., 1993). In agreement with this, hypoxia induced iNOS expression in 
microglial cells has been reported to mediate NO production (Murugan et al., 2011). NO 
produced by microglial iNOS has been reported to contribute to the tissue injury in fetal 
brains (Ohyu et al., 1999) and inhibition of iNOS was beneficial in reducing the volume 
of infarcts (Iadecola et al., 1995).  Elevated level of NO was shown to induce death of 
oligodendrocytes (Merrill et al., 1993) by inhibiting mitochondrial respiration (Baud et 




oxidase in activated microglia could result in generation of peroxynitrite. Peroxynitrite 
is an extremely potent oxidising agent (Brown, 2007) known to exacerbate PWMD by 
being harmful to the immature oligodendrocytes (Haynes et al., 2005).     
1.3.6 Free radicals    
Free radicals generation is a common phenomenon associated with hypoxia. 
They are unstable molecules and are derivatives of oxygen and/or nitrogen. Free 
radicals such as superoxides, hydroxyl radicals and hydrogen peroxide are called as 
reactive oxygen species (ROS) while peroxynitrite decribed above is known as reactive 
nitrogen species (RNS). Multisubunit phagocytic NADPH oxidase comprising P47 
phox, P67 phox, P22 phox, and gp91 phox (Bedard and Krause, 2007) is employed in 
the production of free radicals. Owing to their unstable nature, free radicals are highly 
reactive and are capable of initiating oxidative reactions. Under physiological 
conditions, the excess ROS produced is neutralised by the endogenous anti-oxidant 
defence system. However, when there is a lack of anti-oxidants, ROS promotes 
oxidative stress leading to cellular damage via lipid peroxidation, protein modification, 
and DNA strand breaks. The lack of anti-oxidant defence in the immature brains 
predisposes them to oxidative stress (Buonocore et al., 2001; Welin et al., 2005). In 
response to hypoxic-ischemic insults, a reduction in glutathione content in the 
developing brains has been reported (Wallin et al., 2000). Associated with this, an 
increase in ROS production was demonstrated in the developing white matter (Welin et 
al., 2005) and activated microglia were implicated in the excessive production of ROS 
(Colton et al., 1996). NADPH oxidase (Lavigne et al., 2001; Huo et al., 2011), 




production in microglia (Lavigne et al., 2001; Qin et al., 2004). Consistent with this, is 
the demonstration of increased ROS production by microglia in response to hypoxia 
(Kaur et al., 2009).  ROS produced by activated microglia is known to damage the 
myelin sheath (van der Goes et al., 1998) and is detrimental to the immature 
oligodendrocyte (Haynes et al., 2005) by enabling lipid peroxidation (Griot et al., 1990). 
Lack of antioxidants in PWM has been speculated to be the major cause of 
oligodendrocyte death in PVL (Volpe, 2001). This is supported by the demonstration of 
reduced ROS mediated damage when treated with antioxidants such as edaravone (Kaur 
et al., 2009). 
1.3.7 Iron accumulation 
The developing brain requires high amount of iron, as iron dependant enzymes 
form an integral part of energy metabolism, neurotransmitter synthesis and myelin 
synthesis (Connor and Menzies, 1996; Beard and Connor, 2003).  While deficiency in 
iron could lead to neurological impairments (Beard, 2003; Lozoff and Georgieff, 2006) 
excessive iron could induce oxidative stress (Pinero and Connor, 2000) through ROS 
mediated mechanisms (Halliwell, 1985). In response to hypoxic-ischemic insults, 
increase in iron levels has been demonstrated in the serum and CSF of infants (Shouman 
et al., 2008) and in brains of neonatal rodents (Adcock et al., 1996; Palmer et al., 1999). 
One striking feature in iron loaded brains is the accumulation of iron in microglial cells 
at the foci of lesion. Consistent with this, iron positive AMCs were demonstrated in the 
PWM of hypoxic rats (Kaur and Ling, 1999).  However, the molecular mechanisms by 
which excess iron accumulation in PWM and in AMCs may mediate PWMD in 




1.4 Iron in the developing brain 
Iron deficient rodent models have been of worth in identifying the role of iron in 
the developing brain. Rodent models were used since the sequence of development such 
as the cell migration, myelination, cellular differentiation and expression of 
neuropeptides were similar between rats and human brains (Dobbing, 1972). As stated 
earlier, the developing brain requires high amount of iron to satisfy its high energy 
needs (Pinero and Connor, 2000) and also for normal brain developmental processes 
(Cheepsunthorn et al., 1998) such as myelination and neurotransmitter synthesis (Beard 
et al., 1993).  The critical parameter on which the development of brain depends is the 
continuous supply of iron to the neuronal cells (Roskams and Connor, 1994).  
1.4.1 Iron and neurotransmitter system 
A consistent observation in iron deficiency is the altered monoamine 
neurotransmitter system in the brain. This was explained by the involvement of iron 
dependent enzymes in the synthesis of neurotransmitters such as dopamine, serotonin 
and norepinephrine (Beard et al., 1993). The rate limiting enzymes involved in the 
neurotransmitter synthesis such as the tryptophan hydroxylase and tyrosine hydroxylase 
are dependent on iron for their activity. In addition, monoamine oxidase which is 
required for the proper degradation of monoamine neurotransmitters is also iron 
dependent (Beard, 2003). Apart from these biochemical roles of iron, some common 
findings include (1) iron localisation to the dopamine neurons (Wigglesworth and 
Baum, 1988), (2) increased extracellular dopamine and norepinephrine in regions of 
iron deficiency (Erikson et al., 2001) and (3) the decreased density of dopamine 




dopamine transporters.  Along with dopamine, metabolism of neurotransmitters 
serotonin and norepinephrine was also affected in iron deficient animal models (Beard 
et al., 1994; Morse et al., 1999). Thus, the disruption of monoamine transmitter system 
occurred in direct proportion to the concentration of available iron. As these 
neurotransmitters are involved in axonal growth and synapse formation, a reduction in 
their levels could lead to reduced number of synapses (Beard, 2003).      
1.4.2 Iron and myelination 
Several clinical studies have demonstrated the vital role played by iron in 
myelination. In children with iron deficiency, numerous behavioural changes (Oski and 
Honig, 1978; Oski et al., 1983; Grantham-McGregor and Ani, 2001) were observed and 
these clinical outcomes were traced to hypomyelination (Oski et al., 1983; Lozoff and 
Georgieff, 2006). In addition, brain iron uptake peaks during the periods of increased 
myelination (Morath and Mayer-Proschel, 2001) and iron availability to the 
oligodendorcytes forms a critical parameter in myelination process. Iron deficiency 
during this period leads to hypomyelination. Most enzymes involved in the synthesis of 
myelin precursors such as cholesterol and fatty acids are iron dependent.  The key 
enzyme glucose-6-phosphate dehydrogenase, involved in the production of 
nicotinamide adenine dinucleotide phosphate (NADPH), which is used in myelin 
synthesis for generation of fatty acids, is iron dependent (Cammer, 1984). Other iron 
requiring enzymes enriched in oligodendrocytes include succinic dehydrogenase, HMG-
CoA reductase, NADH dehydrogenase and dioxygenase (Pinero and Connor, 2000). 
Owing to the high rate of lipid synthesis in oligodendrocytes, along with their high 




oligodendrocytes is specifically oriented towards lipid formation, presumably of myelin. 
The presence of iron dependent enzymes and high energy needs of oligodendrocytes 
could probably explain the need for iron during myelination. 
1.4.3 Iron and energy metabolism 
Iron is an indispensible component of electron transfer chain/ energy metabolism 
as perturbations in iron levels have been shown to influence the activity of 
mitochondrial enzymes such as mitochondrial aconitase, isocitric dehydrogenase, citrate 
synthase and succinate dehydrogenase (Oexle et al., 1999).  Further, iron incorporation 
into cytochromes is essential for ATP synthesis. Compared to other cells of the brain, 
the oligodendrocytes require high levels of ATP in order to maintain the myelin sheath. 
This could probably explain their vulnerability to iron pertubations (Todorich et al., 
2008). In the hippocampus of fetal and neonatal brains, associated with the iron 
deficiency, there was a reduction in the activity of cytochrome c oxidase suggesting 
decreased energy metabolism (de Deungria et al., 2000).  
1.5 Proteins involved in iron transport in the brain 
1.5.1 Transferrin (Tf) 
Tf belongs to the family of iron binding glycoproteins which also include the 
homologue of Tf such as lactoferrin, melanotransferrin, and ovotransferrin (Morgan, 
1996). The Tf molecules possess two domains each of which is capable of binding a 
ferric ion (Harris and Aisen, 1975). Tf mediated influx of iron is considered to be the 
major iron delivery pathway in the brain (Connor and Fine, 1986) though there is uptake 




Tf mRNA increases after birth (Bartlett et al., 1991). In the brain, Tf is synthesised by 
choroid plexus and oligodendrocytes (Connor and Benkovic, 1992). Majority of Tf in 
the brain is localised to oligodendrocytes in brains of rodents (Connor and Fine, 1987) 
and humans (Gerber and Connor, 1989).  Additionally, the increase in Tf mRNA in the 
brain coincides with the maturation of oligodendrocytes (Connor and Fine, 1987). When 
the oligodendrocytes development was compromised, the Tf expression was found to be 
reduced (Connor et al., 1987; Bartlett et al., 1991). Though Tf is mainly involved in iron 
delivery, studies have also shown that Tf is essential for cell proliferation (Laskey et al., 
1988). It was proposed that Tf, by delivering iron, contributed to the cellular 
proliferation (Laskey et al., 1988). Tf mediated iron delivery is facilitated when its 
holoform (diferric Tf) binds to the transferrin receptor (TfR) on the cell surface.   
1.5.2 Transferrin receptor (TfR) 
TfR is a transmembrane glycoprotein formed by dimerization of two monomers. 
There are two forms of TfR identified-TfR1 and TfR2 with TfR1 being more prevalent 
in the brain. Studies to identify the cellular distribution of TfR reported the expression 
of TfR in brain capillary endothelial cells   (Jefferies et al., 1984; Oh et al., 1986; Risau 
et al., 1986; Pardridge et al., 1987; Kalaria et al., 1992), epithelial cells of choroid 
plexus (Giometto et al., 1990), neurons (sivakumarJefferies et al., 1984; Markelonis et 
al., 1985; Oh et al., 1986; Giometto et al., 1990), amoeboid microglia (Kaur and Ling, 
1995) and reactive astrocytes (Orita et al., 1990). While the expression of TfR on 
cultured oligodendrocytes (Espinosa de los Monteros and Foucaud, 1987) was 
demonstrated, the expression of TfR in oligodendrocytes in vivo has not been reported 




differic Tf at neutral pH (Hill et al., 1985). The primary mechanism of iron delivery 
involves the endocytosis of TfR-Tf complex, which is mediated by clathrin (Harding et 
al., 1983; Raub and Newton, 1991).  After the release of iron from Tf in the acidic 
environment of the endosome within the cell, the TfR-Tf complex is re-cycled back to 
cell surface where the Tf is released from the TfR.   
1.5.3 Divalent metal transporter-1 (DMT1) 
DMT1, which was first identified to transport ferrous iron across the apical 
membrane of enterocytes (Gunshin et al., 1997; Tandy et al., 2000), is also required for 
the transport of ferrous iron released from transferrin, from the endosome to cytosol of 
the cell. In the brain, DMT1 expression is visualized in neurons of the striatum, 
cerebellum and thalamus, ependymal cells lining the ventricles, and endothelial cells of 
the brain capillaries (Burdo et al., 2001). In addition, immuno-histochemical studies 
have shown the expression of DMT1 in the astrocytes and oligodendrocytes in the 
hippocampus, cerebral cortex and the striatum (Siddappa et al., 2002). The expression 
of DMT1 on endothelial cells was suggested to have a role in the transport of iron into 
the brain (Burdo et al., 2001). This is in agreement with the demonstration of reduced 
iron in the brains of animals with mutated DMT1 (Farcich and Morgan, 1992; Moos and 
Morgan, 2004). Although the involvement of DMT1 in iron transport into the brain is 
debated (Moos and Morgan, 2004), the need for DMT1 in brain vasculature is accepted 






1.5.4 Ferroportin (FPN1) 
FPN1 is the only known iron exporter essentially involved in the efflux of iron 
from the cell (Ganz, 2005; Ward and Kaplan, 2012). Expression of FPN1 has been 
reported on the endothelial cells of BBB, astrocytes, oligodendrocytes, the choroid 
plexus and ependymal cells (Moos and Rosengren Nielsen, 2006). FPN1 expression has 
been demonstrated on the abluminal side of the blood vessel endothelial cells (Wu et al., 
2004b). Reduced levels of FPN1 have been reported to result in reduced iron levels in 
the brain, by decreasing iron efflux across the BBB (Iacovelli et al., 2009).  
1.5.5 Ceruloplasmin (CP) 
CP is a multicopper enzyme possessing ferroxidase activity which is essential 
for the oxidation of Fe2+ to Fe3+. CP acts in conjunction with FPN1 and facilitate the 
release of iron from the cells.  In brain CP is synthesized and secreted by astrocytes. It is 
mostly present on the astrocytes cell surface in the glycosyl-phosphatidyl-inositol (GPI) 
linked form (Jeong and David, 2003). A recent finding is that GPI-coupled CP is 
essential for maintaining FPN1 expression, as loss of GPI-CP could result in 
disappearance of FPN1 (De Domenico et al., 2007). Astrocytes expressing CP have 
been found in close association with blood vessels of the brain, and are proposed to be 
involved in the conversion of ferrous iron released by endothelial cells into ferric form 
(Moos et al., 2007; Benarroch, 2009). Astrocytes are suggested to be involved in iron 
distribution in the brain (Dringen et al., 2007) and GPI-CP could act as a key regulator 
in releasing iron from the astrocytes to meet the requirements of neurons and other brain 




1.6 Mechanism of iron transport in the brain 
As a measure of protection, the brain and its neuropil is compartmentalized from the 
peripheral circulation by a vascular barrier, called the BBB and the blood CSF barrier. 
As explained previously, the BBB is formed by the tight junctions of endothelial cells, 
which restricts the entry of certain metabolites into the brain from the blood. Iron is one 
among those substances with restricted entry, which requires a tightly regulated 
pathway. The luminal surface of endothelial cells expresses TfR, through which, the 
entry of iron into the brain is accomplished (Bradbury, 1997; Abbott et al., 2006; Moos 
et al., 2007). On binding with differic-Tf, the TfR-Tf complex is endocytosed into the 
endothelial cell. A change in pH within the endosome in the endothelial cell causes the 
release of iron from Tf. The iron from the endosome is then released into the cytosol 
through DMT1. The released iron in the cytosol is exported to the brain via the FPN1 
expressed on the BBB (Wu et al., 2004b). The exported iron in the ferrous form is 
oxidized to ferric form by CP present on the astrocytic foot processes associated with 
the BBB (Jeong and David, 2003). The conversion to ferric form enables the binding of 
iron to the Tf present in the brain interstitial fluid (Rouault and Cooperman, 2006). The 
Tf bound iron is utilized by the glia and the neurons by TfR dependent mechanisms. 
Although Tf mediated iron transport is considered the main route of iron transport, 
existence of non-Tf bound iron transport came into lights with the demonstration of 
normal iron levels in hypotransferrinemic mice (Beard et al., 2005). Though iron could 
traverse BBB by binding to the lactoferrin and melanotransferrin (the homologues of 
transferrin) (Fillebeen et al., 1999), the potential of this transport is unclear (Richardson 




to be only 10% of that of serum Tf. Owing to the high requirement of iron by the brain, 
the existence of non-transferrin bound iron (NTBI) could not be neglected.  As some 
studies indicated that oligodendrocytes lack TfR expression in vivo, NTBI was 
suggested to be the major source of iron for oligodendrocytes to carry out myelination 
process (Takeda et al., 1998; Todorich et al., 2009).        






Fig II: A schematic diagram representing the transport of iron into the brain through 
the blood brain barrier formed by endothelial cells and tight junctions (TJ). The ferric 
iron (Fe3+) on binding to transferrin (Tf) in plasma, is taken up by the endothelial 
cells via the transferrin receptors (TfR). The iron taken up by the endothelial cells is 
released into the brain as ferrous iron via ferroportin (FPN1) expressed on the 
abluminal side of endothelial cells. The protein ceruloplasmin (CP) expressed on 
blood vessels and in end feet of astrocytes favours the oxidisation of released ferrous 
iron to ferric form enabling its binding to the brain interstitial Tf. Kindly see the text 




In addition, several other routes by which iron transport could occur in the brain 
have been proposed. For example the gap junctions, which connect the astrocytes with 
other glial cells, could serve as an alternative route of iron transport (Bennett et al., 
2003). Ferritin molecules are suggested to travel down the axons to the synapses 
(Rouault and Cooperman, 2006). In addition, FPN1 expressed on the synaptic 
membrane could favour the release of ferrous iron (Wu et al., 2004b). The released iron 
or ferritin could be taken up by the post synaptic neurons/glial cells which express iron 
uptake proteins such as TfR and DMT1 (Connor and Menzies, 1995; Moos et al., 2007) 
or via ferritin binding receptors such as the Scara 5 (Li et al., 2009) and Tim 2 
(Todorich et al., 2008).  
                                 
 
 
Fig III: Schematic diagram representing iron influx into the cell and iron efflux from 
the cell. The di-ferric transferrin bound to transferrin receptor (TfR) is endocytosed 
into the cell. The Fe3+ released inside the endosome is converted to Fe2+ by 
STEAP3 and transported to the cytosol via divalent metal transporter (DMT1). The 
released Fe2+ in the cytosol is either utilized by mitochondria or remains bound to 




1.7 Regulation of iron homeostasis 
Pertubations in iron levels within the brain have been reported to result in 
deleterious effects leading to neurobehavioral abnormalities or neurodegeneration 
(Pinero and Connor, 2000). Therefore, there is a requirement for a regulatory 
mechanism to maintain the iron levels in the brain. The molecules engaged in regulating 
iron levels are hepcidin, iron regulatory proteins (IRP1, IRP2) and HIF-1α.  
1.7.1 Hepcidin 
Hepcidin synthesised in the liver, is a peptide hormone and is the major 
regulator of iron homeostasis (Ganz, 2003). Hepcidin restricts the iron efflux from a cell 
by negatively regulating FPN1 expression. When there is increased concentration of 
iron in plasma and in conditions such as inflammation or hypoxia, hepcidin binds to 
FPN1 resulting in phosphorylation, internalization, ubiquitination and degeradation of 
FPN1 (Nemeth et al., 2004; De Domenico et al., 2007). Hepcidin mRNA has been 
recently reported to be expressed in the murine brain (Zechel et al., 2006; Wang et al., 
2010).  On injecting synthetic hepcidin into cerebral ventricles, decreased expression of 
FPN1 was reported in striatum, hippocampus and cerebral cortex (Wang et al., 2010). 
Further treatment of cultured neurons with hepcidin resulted in diminished iron efflux 
and FPN1 expression (Wang et al., 2010). Furthermore, Ding et al. (2011) showed the 
up-regulation of hepcidin in ischemic brain and this was attributed to the decreased 
FPN1 expression, leading to iron accumulation in ischemic brains. Based on these 
observations, it was speculated that hepcidin could play a major role in regulating iron 




1.7.2 Iron regulatory proteins (IRPs) 
Iron regulatory proteins also called as iron responsive elements (IREs)-binding 
proteins, are the regulators of cellular iron homeostasis. The mechanism by which they 
regulate iron transport is by means of binding to the consensus sequence termed IREs, 
located on either in the 5’ or 3’ end of the mRNA of proteins involved in iron transport. 
While the binding ability of IRP1 depend on the presence of iron-sulphur cluster in the 
IRP1 (Hirling et al., 1994; Iwai et al., 1995), the IRE binding ability of IRP2 solely 
depends on the iron concentration existing within the cell (Rouault, 2006). The IRP/IRE 
interaction post-transcriptionally influences the expression of proteins involved in iron 
transport. When IRPs bind to IRE sequence in the 5’ end they result in down-regulation 
in the expression of proteins whereas, binding to the 3’ end favours the up-regulation of 
protein. For example, when there is a need for iron by the cell the IRPs bind to IREs in 
the 3’ UTR of TfR and DMT1 mRNAs. At the same time, IRE/IRP interaction occurs in 
the 5’ UTR of ferritin and ferroportin. This could promote cellular iron uptake 
(Thomson et al., 1999). Alternatively, in iron replete cells, IRE/IRP interaction 
disappears favouring the translation of ferritin and ferroportin. There are several other 
proteins such as hypoxia-inducible factor 2α, 5-aminolevulinic acid synthetase and 
amyloid precursor protein which possess IRE sequence in their 5’ end. Apart from 
intracellular iron levels, the IRE/IRP interaction is also influenced by oxidation, 
nitration or by peroxynitrite (Cairo et al., 2002). In embryos lacking both IRPs, their 
death happens at the blastocyst stage before implantation (Smith et al., 2006). In mice 




et al., 2004; Cooperman et al., 2005). These findings imply the importance of IRP 
mediated iron regulatory system.    
 
 




                                    
Fig IV: Schematic Diagram representing the mechanism by which IRPs 
regulate iron homeostasis. A: When IRP binds to IRE in the mRNA of TfR 
and DMT1 the expression of TfR and DMT1 is up-regulated. Under high 
iron levels IRP is released from IRE resulting in degradation of mRNA of 
TfR and DMT1. B: Contrary to TfR and DMT1, when IRP binds to IRE in 
the mRNA of ferritin and ferroportin their translation is inhibited. When the 
required iron level is achieved in the cell or under high iron levels the IRP-





1.7.3 Hypoxia inducible factor-1 
HIF-1, a transcription factor stabilised due to hypoxia, facilitates the adaptation 
of the cells to hypoxic environment (Wang et al., 1995; Semenza, 1998). HIF-1 was first 
identified during the search for hypoxia responsive element in the 3’ enhancer of 
erythropoietin gene (Goldberg et al., 1988; Semenza et al., 1991). HIF-1 consists of a 
hypoxia inducible HIF-1α subunit and constitutively expressed HIF-1β subunit (Wang 
et al., 1995). The stabilization and translocation of HIF-1α to the nucleus is essential to 
form the functional HIF-1 (Huang et al., 1996; Kallio et al., 1997). The link between 
hypoxia and iron metabolism was obtained from seminal studies which showed the 
increased iron accumulation in response to hypoxia (Mendel, 1961; Simpson, 1992). 
Further hypoxia was shown to increase the expression of proteins involved in iron 
transport such as Tf (Rolfs et al., 1997), TfR (Tacchini et al., 1999), hemeoxygenase-1 
(Wu et al., 2004a), CP (Mukhopadhyay et al., 2000) and DMT1 (Lis et al., 2005). 
Indeed, it was later demonstrated that the promoters of TfR, CP and DMT1 possessed 
the HRE sequence to which HIF-1 binds with great affinity (Tacchini et al., 1999; 
Mukhopadhyay et al., 2000; Qian et al., 2011). Binding of HIF-1 to HRE was suggested 
to favour the up-regulation of TfR, CP and DMT1 in hypoxia. This may be the same 
with other proteins up-regulated by hypoxia.        
1.8 Iron and glial cells 
1.8.1 Microglia 
Microglia, the resident macrophages of the brain, are implicated in iron 
homeostasis of the brain (Zhang et al., 2006). In the rat brain, microglial cells were 




1993). Iron was not only localised in microglia but was also found in neurons and 
oligodendrocytes (Benkovic and Connor, 1993). During development, the microglial 
cells in the white matter were found to be initially positive for iron. Later, during the 
course of development, iron staining was found in oligodendrocytes (Connor et al., 
1995). As myelination proceeds, numerous iron positive oligodendrocytes were visible 
in the white matter replacing the iron positive microglia (LeVine, 1991; Connor, 1994). 
This transfer of iron to oligodendrocytes from microglia was facilitated through H-
ferritin released by microglia (Zhang et al., 2006). However, when the microglial cells 
are activated, the trophic effect could be reverted by the toxic factors produced by 
microglia (Zhang et al., 2006) leading to death of oligodendrocytes (Lehnardt et al., 
2002).  Activation of microglia is often accompanied by iron accumulation. Presence of 
cytokines such as TNF- α and transforming growth factor-β (TGF-β) has been 
demonstrated to favour the accumulation of iron in microglia (Rathore et al., 2012). The 
iron accumulated within microglia is reported to influence the production of matrix 
metalloproteinases (Mairuae et al., 2011) and cytokine secretion by microglia (Zhang et 
al., 2006). Apart from this, as microglia are a source of free radicals and iron can 
catalyse free radical production, it is possible that the increased iron within microglia 
could induce tissue damage by either enhancing free radical production or by increasing 
the production of pro-inflammatory cytokines. In response to hypoxic exposure, iron 
positive microglial cells were reported in developing PWM (Cheepsunthorn et al., 1998; 
Kaur and Ling, 1999), but the significance of this iron accumulation by microglia has 






Astrocytes are considered to be the major players of iron metabolism in the brain 
(Hoepken et al., 2004). Astrocytic end-feet which are in close proximity to the brain 
capillaries possess both iron influx and efflux proteins and hence, they are majorly 
implicated in the iron transport into the brain from the brain capillaries (Dringen et al., 
2007). Astrocytes are suggested to have high capacity to store excess iron, owing to the 
ability of cultured astrocytes to accumulate high levels of iron when treated with ferric 
ammonium citrate (Hoepken et al., 2004; Tulpule et al., 2010), but, generally they do 
not contain large amount of iron (Dringen et al., 2007). In conditions such as 
aceruloplasmia, in which there is lack of CP, iron accumulates within astrocytes 
(Kaneko et al., 2002; Oshiro et al., 2008) and this accumulation of iron within the 
astrocytes renders them susceptible to oxidative stress (Robb and Connor, 1998). 
Additionally, when the efflux of iron from astrocytes is impaired, there is a reduction in 
iron levels in neurons (Jeong and David, 2006) and in microglia (Schulz et al., 2012) 
justifying the role of astrocytes in iron trafficking (Dringen et al., 2007).   The role of 
iron within astrocytes remains unexplored as the physiological requirement of iron by 
astrocytes is very low (Dringen et al., 2007). Schulz et al (2012) demonstrated the need 
for iron efflux from astrocytes in the remyelination process in animal models of 
lysophosphatidylcholine induced demyelination. 
1.8.3 Oligodendrocytes 
In normal adult brain, oligodendrocytes are the principal cells staining for iron 
(Benkovic and Connor, 1993; Connor et al., 1995; Connor and Menzies, 1996). In white 




2008). The acquisition of iron by oligodendrocytes is attributed to their role in myelin 
production, yet, the presence of iron enriched oligodendrocytes even in lower animal 
brains (Erb et al., 1996), in which there is minimal myelination, suggests that iron is 
required for the metabolic processes of oligodendrocytes (Todorich et al., 2008). In 
developing brain, the presence of iron positive oligodendrocytes were observed during 
the second postnatal week and these oligodendrocytes were found at the foci of 
myelination (Connor and Menzies, 1996). If oligodendrocyte maturation fails, then iron 
was found to be accumulated by astrocytes or microglia (Connor and Menzies, 1990), 
whereas, if maturation of oligodendrocytes continued, iron accumulated in 
oligodendrocytes, though the myelin produced was abnormal (LeVine, 1991; Connor, 
1994).  Thus, it was suggested that accumulation of iron by oligodendrocytes is 
essential for the onset of myelination (Connor and Menzies, 1996). Consistent with this, 
is the demonstration of hypomyelination in humans and rodents, in association with iron 
deficiency (Ortiz et al., 2004; Beard, 2008; Wu et al., 2008). In several studies, the 
expression of myelin proteins such as MBP and proteolipid protein (PLP), lipids and 
cholesterol were reported to be reduced owing to the iron deficient food fed to early 
postnatal rodents (Yu et al., 1986; Ortiz et al., 2004). In addition, oligodendrocytes 
synthesise high levels of ATP to maintain the myelin sheaths, and for that they require 
constant supply of iron (Todorich et al., 2008). It was proposed that the high iron 
content of oligodendrocytes along with their reduced anti-oxidant system renders them 
highly susceptible to oxidative stress (Thorburne and Juurlink, 1996; Hemdan and 
Almazan, 2007). Under conditions such as hypoxia-ischemia, oligodendrocytes 
accumulate non-protein bound iron (Volpe, 2001) which could lead to their death 
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through free radicals generation. However, treatment with deferoxamine was proven 
beneficial in reducing the free radical mediated damage to the oligodendrocytes (Back 
et al., 1998). 
1.9 Aims 
As explained above, though iron is essential for the normal developmental process, 
excess iron accumulation could lead to oxidative stress induced tissue injury. In intra-
cerebral haemorrhage animal models, iron overload has been implicated in the damage 
of brain tissue (Wagner et al., 2003; Nakamura et al., 2006). Hypoxic insults have been 
reported to increase the serum iron levels and iron levels in CSF in infants (Shouman et 
al., 2008). Even experimental studies in animals have shown the accumulation of iron in 
brains, in response to hypoxia (Adcock et al., 1996; Palmer et al., 1999).  Though it has 
been speculated that iron accumulation could be involved in the pathogenesis of 
PWMD, its role in causing such damage is yet to be elucidated and this forms the 
primary aim of this study. 
1.9.1   To investigate if iron accumulates in PWM in response to hypoxia  
 Previous reports have suggested that iron supplementation could lead to 
exacerbation of periventricular leukomalacia (Dommergues et al., 1998). In 
accordance with this, Inder et al (2002) demonstrated the presence of peroxidation 
products in the CSF of premature infants who suffered white matter injury. In 
addition, Gu et al. (2009) reported that the white matter damage caused due to intra-
cerebral haemorrhage in piglets was reduced following administration of the iron 
chelator, deferoxamine. Based on the above, it was hypothesized that PWM may 
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accumulate iron in response to hypoxic exposure. To address this the following 
were done: 
 The concentration of iron at different time points varying from 3h to 14 d was 
analysed in PWM of hypoxic animals along with that of age-matched controls  
 Dysregulation of iron metabolism by iron regulatory proteins has been proposed to 
lead to iron accumulation and subsequent tissue damage (Oshiro et al., 2011). 
Hence, the expression of iron regulatory proteins (IPR1, IRP2) and HIF-1α, known 
to induce genes involved in iron metabolism was studied in hypoxic PWM.   
 In addition, the increase in iron levels could be contributed by excessive release of 
iron from brain capillary endothelial cells into the PWM.  Hence the expression of 
proteins involved in iron transport such as the TfR, DMT1, FPN1 and CP was 
studied in PWM. By immunofluorescence the cellular distribution of these proteins 
was studied in the endothelial cells of blood vessels in PWM, as iron trafficking 
across the BBB is essential for the increase in iron levels in the hypoxic PWM. 
1.9.2 To determine the cellular localisation of iron and the pathways of iron 
metabolism in the glial cells in hypoxic PWM 
 In response to hypoxic-ischemic injuries, some studies have previously 
demonstrated the presence of iron positive cells in the PWM (Cheepsunthorn et 
al., 1998; Kaur and Ling, 1999). Although based on the morphology, these cells 
were identified as microglial cells (Cheepsunthorn et al., 1998; Kaur and Ling, 
1999) the type of glial cell which accumulates iron in response to hypoxia, has 
to be ascertained by double labelling with specific markers. For this, Perls’ iron 
staining was performed on hypoxic brain sections and then labelled for glial 
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cells with markers such as Lectin from tomato (Lycopersicon esculentum) (a 
marker for microglia and blood vessels), GFAP (a marker for astrocytes) and 
CC1 (a marker for oligodendrocytes).     
 As explained earlier, molecules such as IRPs and HIF-1α are essential in 
maintaining the cellular iron levels by regulating the expression of proteins 
involved in iron transport such as TfR, DMT1, FPN1 and CP. Their 
dysregulation has been reported to contribute to iron imbalance in the cells. 
Hence, the changes in the expression of these proteins were studied using double 
immunofluorescence in the three glial cell types.   
 The dysfunction of iron regulatory mechanism and associated iron uptake 
pathway was studied using microglial cultures, as AMCs of hypoxic PWM were 
found to accumulate more iron when compared to other glial cells. The role of 
HIF-1α in causing iron accumulation in hypoxic microglia, was studied by 
subjecting the primary microglial cells to hypoxia with KC7F2 (an HIF-1α 
inhibitor) added to the culture medium. In addition, the expression of IRPs was 
also studied to identify additional iron regulatory measures in the hypoxic 
microglia. 
1.9.3 To investigate the role of iron within hypoxic microglia and in causing 
PWMD 
 Activated microglia are suggested to be the primary source for cytotoxic factors 
such as NO and inflammatory mediators (Kaur et al., 2007). Based on the fact 
that iron overloaded microglia resulted in enhanced cytokines secretion when 
challenged with lipopolysaccharides (Zhang et al., 2006), the role of hypoxia 
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induced iron accumulation in microglia was analysed to determine if iron 
mediated the cytokine production in hypoxic microglia. In addition, increased 
iron is a well-known inducer of free radical production and, as microglia are 
known to generate ROS (Kaur et al., 2009), the involvement of iron in this was 
also evaluated. The role of iron in hypoxic microglial cells was elucidated using 
the iron chelator, deferoxamine. 
 Free radicals and cytokines produced by microglia have been implicated in the 
damage of oligodendrocytes (Casaccia-Bonnefil, 2000; Pouly et al., 2000; Back 
et al., 2002; Haynes et al., 2005). Associated with this, was the demonstration of 
apoptosis of oligodendrocytes when treated with conditioned medium from 
microglia challenged with lipopolysaccharide (Pang et al., 2000).  Hence the 
effect of iron overload in hypoxic microglia on oligodendrocytes was 
investigated by subjecting the primary oligodendrocytes to treatment with 
conditioned medium from hypoxic microglia. In this connection, the changes in 
glutathione levels, lipid peroxidation, caspase-3 labelling and proliferation rate 
was analysed in oligodendrocytes, to identify the mechanism through which the 
toxic factors secreted by iron accumulated hypoxic microglia could damage the 
oligodendrocytes. 
 Moreover, microglial cells are known to produce matrix metalloproteinase-9 
(MMP-9) (Leonardo et al., 2009) which is implicated in the damage of BBB. 
MMP-9 does this by digesting the basal lamina of the BBB resulting in the 
increased permeability of BBB (Rosenberg et al., 1998). A recent study has 
shown that, in response to iron accumulation in microglia, there was an 
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increased production of MMP-9 (Mairuae et al., 2011). Based on the above, 
whether iron accumulation in AMCs in hypoxic PWM could result in MMP-9 
production was analysed. The role of iron in this process was studied by using 
hypoxic animals treated with deferoxamine. 
 Besides the above, the mechanistic action of deferoxamine in attenuating 
inflammatory reactions induced by hypoxic microglia was studied. 
Deferoxamine, used for treating patients with iron overload, is a well-known 
iron chelator in clinical practice for more than 30 years (Selim, 2009). Past 
investigations identified deferoxamine to possess antioxidant property (Peeters-
Scholte et al., 2003) and neuroprotective effects such as reduced lipid 
peroxidation and improved cerebral perfusion (Selim, 2009). In animal models 
of hypoxic-ischemia, deferoxamine resulted in reduced brain edema volume 
(Palmer et al., 1994) and was demonstrated to suppress microglial activation 
(Wu et al., 2011; Miao et al., 2012), yet, the mechanisms through which 
deferoxamine modulates the microglial response remains unexplored. Besides, 
as HIF-1α could contribute to the iron uptake, the mechanism of action of HIF-
1α inhibitor, KC7F2 was also examined to identify whether KC7F2 too 
exhibited the same effect as that of deferoxamine. To accomplish this, mitogen 
activated protein kinases (MAPKs) were studied as they are a family of proteins 
well known to respond to a wide range of stimuli (Chang and Karin, 2001). The 
MAPK family consisting of ERK, P38 and JNK are demonstrated to mediate 
ROS and cytokines production in microglia (Koistinaho and Koistinaho, 2002; Ji 
and Suter, 2007; Huo et al., 2011). Indeed MAPKs mediated the inflammatory 
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pathway in hypoxic microglial cells (Deng et al., 2008). Based on this, the 
differential expression of MAPKs and their downstream targets were studied in 
hypoxic microglia to identify the pathway through which deferoxamine mediates 
its anti-inflammatory action.  
1.9.4  To investigate the role of iron accumulated within hypoxic oligodendrocytes 
 Oligodendrocytes are iron enriched cells in the brain and their susceptibility to 
damage was attributed to their high iron content (Thorburne and Juurlink, 1996). 
In response to hypoxia, in PWM, though multiple factors result in the selective 
damage of oligodendrocytes, changes in iron levels within oligodendrocytes, 
may also account for their death. Ferritin was suggested to be increased in 
hypoxic oligodendrocytes to store the excess iron (Qi and Dawson, 1994). 
Hence it is possible that the increase in iron levels could contribute to their 
damage in hypoxic conditions. To elucidate this, oligodendrocyte cultures were 
subjected to hypoxia and the changes in iron levels and the pathway by which 
their apoptosis occurs in response to iron content was analysed with a special 
focus on endoplasmic reticulum stress (ER stress) pathway in these cells. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Animals 
One day old Wistar rats were used for this study, as the development of white 
matter in these pups is comparable to the development in midgestation in human 
(Sheldon et al., 1996). For in vivo studies, a total of 217 Wistar rats were used and the 
total number of rats used for various experiments is listed in Table 1. A total of 168 rat 
pups were used for setting up primary cultures. All experiments were performed 
complying to the approved guidelines as per Institutional Animal Care and Use 
Committee, National University of Singapore.   
2.1.1 Hypoxic conditioning for in vivo experiments 
The one day old rat pups were subjected to hypoxia by placing them in a 
multigas chamber (Sanyo, Biomedical Electrical, Tokyo, Japan; Model: MCo-18M) 
filled with 95% N2 and 5%O2 for 2 h. Equal number of age matched controls were kept 
outside the chamber. The rats subjected to hypoxic exposure were then allowed to 
recover under normoxic conditions before sacrifice at 3h, 24h, 3d, 7d and 14d along 
with their age matched controls.  
2.1.2 Drug treatment for in vivo experiments 
Pharmacological agent deferoxamine, an iron chelator, was used in this study to 
elucidate the role of iron in causing PWMD. Deferoxamine was dissolved in distilled 
water and administered at a concentration of 150mg/kg body weight (Papazisis et al., 
2008). In rats subjected to hypoxia, an intra-peritoneal administration of deferoxamine 
was performed immediately after the hypoxic exposure, followed by a second injection 
24 hours later.  
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Table 1: Total number of rats sacrificed for protein extraction, iron assay, double 
immunofluorescence and for iron staining at different time points following 
hypoxic exposure (H) and their corresponding age matched controls (C). Number 
of animals treated with deferoxamine (H+D) is also listed. 









Iron assay Iron 
staining 
C H H+D C H C H C H 
1d [3h] 15 15 3  3 
2d [24h] 15 15 3  3 
4d [3d] 14 14 3 15 15 3  3 3 3 
8d [7d] 15 15 3  3 
15d [14d] 15 15 3  3 
2.2 Primary glial culture 
2.2.1 Materials required 
4’, 6- diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma, USA, Cat. No. 
D1306) 
70μm nylon cell strainer (BD Biosciences, USA, Cat. No. 352350) 
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75cm2 tissue culture flasks (CORNING, Tewksbury, MA, USA) 
Antibiotic-antimycotic solution (100X Sigma-Aldrich, USA, Cat.No. A5955) 
Deoxyribonuclease I (Sigma-Aldrich, USA, Cat.No. D4527) 
Dulbecco's Modified Eagle Medium (DMEM) (Sigma, USA, Cat. No. D1152) 
Ethylenediaminetetraacetic acid (EDTA) (10X Sigma, USA, Cat. No. E-7889) 
Fetal bovine serum (FBS) (Invitrogen, USA, Cat. No. 10099) 
Insulin from bovine pancreas (Sigma-Aldrich, USA, Cat. No. I0516) 
Non-essential amino acid (Sigma, USA, Cat. No. M7145) 
Phosphate buffered saline (PBS) (0.1M, pH 7.4) 
Platelet-derived growth factor (PDGF) (Sigma, USA; Cat No. P3201) 
Sodium pyruvate (Sigma, USA; Cat No. P2256) 
Sodium selenite (Sigma, USA; Cat No. S5261) 
Transferrin (Sigma, USA; Cat No. T1147) 
Triiodothyronine (Sigma, USA; Cat No. T2752) 
Trypsin - EDTA (10X Sigma, USA, Cat. No. T4549) 
Complete medium for primary mixed glial cultures 
DMEM 450 ml 
Antibiotic (100X) 5 ml 
FBS 50 ml 
Non-essential amino acids 5 ml 
Insulin 625 μl 
Defined medium for primary oligodendrocyte cultures 
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DMEM 95.5 ml 
FBS 0.5 ml 
Insulin (5 μg/ml stock) 50 μl 
Transferrin (2mg/ml stock) 2.5 ml 
Sodium pyruvate (100 mg/ml stock) 110 μl 
Sodium selenite (2.5 mg/ml stock) 0.2 μl 
Triodothyronine (20 µg/ml stock) 100 μl 
Antibiotic (100X) 1 ml 
To every 10 ml of oligodendrocyte complete medium 150 μl of FBS and 0.1μl of 
growth factors namely PDGF and FGF each are added before adding to the culture. 
2.2.2 Procedure 
2.2.2.1 Removal of cerebral cortices 
Mixed glial cultures were prepared by using cerebral cortices from 1 day old rat 
pups by following the method of Giulian and Baker (1986). The one day old rat pups 
were deeply anesthetized using 6% sodium pentobarbital at a concentration of 60mg/kg 
body weight. The animals were then wiped with 70% alcohol. The scalp was incised 
along the midline to expose the brain. The cortex was excised and placed in a Petri dish 
containing ice cold PBS.  
2.2.2.2 Preparation of mixed glial culture 
After rinsing the tissues three times in ice cold PBS, the meninges from the 
cortices were removed. Having ensured the complete removal of meninges the tissues 
were dissociated by means of trypsinization. In brief, the tissues free of meninges and 
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blood vessels were transferred to a Petri dish containing dissociating medium (18 ml of 
DMEM, 2ml of 10X Trypsin-EDTA, 200µl of DNase). The tissues were cut down into 
small pieces with the help of tissue scissors and then mechanically dissociated by means 
of aspirating them up and down with the help of 10 ml pipette into a 50ml centrifuge 
tube. The dissociated contents were then transferred to a 75cm2 culture flask and placed 
on a shaker at 200rpm for 15 min to enable the formation of single cell suspension. The 
suspension was filtered through a 70µm cell strainer to remove any clumps. The filtrate 
was centrifuged at 1000 rpm for 5 min. The pellet containing cells was re-suspended 
and plated at a density of 1 X 106/ml of DMEM containing 10% FBS, antibiotics, 
insulin and non-essential amino acids and placed in humidified chamber at 37ºC. The 
culture medium was changed on alternative days until it reaches confluence. 
2.2.2.3 Purification of microglia 
After two weeks, the microglial cells were purified from the mixed cultures by 
means of mild trypsinization following the method described by Saura et al (2003).  In 
brief, the cultures were treated with trypsinizing solution (39 ml of DMEM, 1 ml of 
0.25% trypsin and 20 µl of 0.5M EDTA) for 10 min. The membrane containing 
astrocytes and oligodendrocytes was detached from the surface of the culture flask and 
subsequently removed. The microglial cells, which remained attached to the bottom of 
the culture flasks, were cultured in DMEM containing 10% FBS. The next day, the 
microglial cells were detached from the surface of the flask by trypisinization (2X 
Trypsin-EDTA in PBS) and were seeded at a density of 2.5 X 105 cells in a 24 well 
plate for immunocytochemistry; 1 X 106 cells per 75 cm2 flask for protein extraction 
and reactive oxygen species analysis.  
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 The purity of microglial cells was assessed by labelling them with the anti-OX42 
(1:100) (catalog #O-MAS 3706; Harlan-Sera Laboratory), a specific marker for 
microglia and DAPI (20 µg/ml; Sigma-Aldrich), a nuclear marker for all cells. The 
purity of the microglial cultures was observed to be around ~ 96%. 
2.2.2.4 Astrocyte-Oligodendrocyte co-culture 
 During the purification of microglia from mixed glial cultures, the membrane 
containing astrocytes and oligodendrocytes was detached from culture flask surface. 
This detached membrane was further mechanistically dissociated and filtered through 
70µm cell strainer to remove any clumps. The filtrate was spinned at 1000 rpm for 5 
min and the dissociated cells were seeded at a density of 1 X 106 cells per ml of DMEM 
in a 75 cm2 flask. The culture medium was changed on alternate days until reaching 
confluence. 
2.2.2.5 Oligodendrocyte cultures 
 The oligodendrocyte cultures were prepared by following the method of 
McCarthy and deVellis (1980). The oligodendrocytes were purified from the astrocytes 
by shaking the culture flask at 200 rpm for 16 hours. After 16 hours of shaking, the 
purified oligodendrocytes remained in the suspension while the astrocytes remained 
attached to the flask. The suspension containing oligodendrocytes was filtered and 
centrifuged. The pellet was then re-suspended in defined medium for oligodendrocytes 
as described by Armstrong (1998), and seeded in a 75 cm2 flask at a density of 1 X 106 
cells per ml of defined medium. For immunofluorescence studies, the cells were seeded 
at a density of 2.5 X 105 cells in a 24 well plate.   
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 The purity of oligodendrocytes was assessed by using the oligodendrocyte 
marker CC1 (1:20) (Millipore Biosciences; Cat No.OP80) (Bhat et al., 1996) and DAPI. 
The purity of oligodendrocyte cultures used in this study was ~ 96% pure. 
2.3 Treatment of primary cultures 
2.3.1 Hypoxia conditioning of cells 
 For all the experiments, the nutritional medium of primary cultures was replaced 
with serum free DMEM and then subjected to various treatments. Hypoxic conditioning 
of the primary cultures was done by placing them in a multigas chamber (model 18M; 
multigas incubator; Sanyo) containing 94% N2, 5% CO2 and 1% O2 at 37°C for 4 hours. 
The control cultures were placed in the incubator filled with 95% air and 5% CO2 at 37° 
C.    
2.3.2 Treatment of primary microglial cells 
 Drugs deferoxamine, KC7F2, U0126, SB202190 and SP600125 were used to 
elucidate the mechanism involved in iron mediated PWMD. Iron chelator deferoxamine 
(Sigma-Aldrich; catalog #D9533) was used to study the role of iron in causing PWMD.  
KC7F2 (Millipore, Catalog # 400088), a HIF-1α translational inhibitor, was used to 
study the role of HIF-1α in causing in iron uptake in hypoxic microglial cells. U0126 
(ERK inhibitor; SA biosciences, Catalog #FA003), SB202190 (P38 inhibitor; SA 
biosciences, Catalog #FA-004) and SP6000125 (JNK inhibitor; SA biosciences, Catalog 
#FA-005) were used to study the role of MAPK kinases in hypoxic microglial cells 
treated with/without deferoxamine. 
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Group-1 cultures were used to study the time dependant changes in the expression of 
proteins TfR, DMT1 and HIF-1α in the purified microglial cultures. The cultures were 
subjected to varying duration of hypoxia ranging from 2h to 6h.  
Group-II cultures were used to study if HIF-1α indeed regulated the expression of 
proteins involved in iron uptake such as the TfR and DMT1. For this, the cultures were 
treated with HIF-1α translational inhibitor KC7F2. KC7F2 has been previously 
demonstrated to down regulate the genes induced by HIF1α. The concentration of 
KC7F2 used in this study was 40 µM (Narita et al., 2009).  
Group III cultures were used to analyse if iron regulatory proteins (IRP1 and IRP2) 
expression was altered in hypoxic microglia 
Group IV cultures were used to study the role of iron in microglia in response to 
hypoxic exposure. For this the microglial cultures were subjected to hypoxia with 
deferoxamine (100µM; Zhang et al. 2006) added to the medium. 
Group V cultures were used to elucidate the involvement of MAPK pathway in 
deferoxamine mediated inhibition of inflammatory cytokines production in microglia. 
In addition, the mechanistic action of KC7F2 was simultaneously analysed. The 
purified microglial cells were subdivided into 6 sets- control (C), control with KC7F2 
(C+K), control with deferoxamine (C+D), hypoxia (H), Hypoxia + KC7F2 (H+K) and 
hypoxia + deferoxamine (H+D). The concentration of deferoxamine used was 100 µM 
(Zhang et al., 2006). 
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Group VI cultures were used to study the downstream processing of MAPK pathways. 
While the mechanistic action of ERK1/2 was studied with the help of U0126, that of 
P38 and JNK was studied using SB202190 and SP600125, respectively.  The microglial 
cells were subdivided according to the treatment as control (C), control + KC7F2 
(C+K), control + deferoxamine (C+D), control + U0126 (C+U), control +SB202190 
(C+P), control + SP600125 (C+J), hypoxia (H), Hypoxia + KC7F2 (H+K), hypoxia + 
deferoxamine (H+D) and hypoxia + U0126 (H+U), hypoxia + SB202190 (C+P) and 
hypoxia + SP600125 (C+J).  U0126 was used at a concentration of 20 µM (Kim et al., 
2005) to explore the role of ERK. The concentrations of SB202190 (a P38 specific 
inhibitor) and SP600125 (a JNK specific inhibitor) used in this study were 5 µM 
(Markovic et al., 2009) and 1 µM (Deng et al., 2008) respectively. 
2.3.3 Treatment of primary oligodendrocytes 
 Indirect pathway leading to death of oligodendrocytes- For elucidating the effect of 
iron accumulation in hypoxic microglia on oligodendrocytes, control cultures were 
used and split into various groups based on their treatment (explained later under 
each subheading).  
 Direct pathway leading to death of oligodendrocytes- For investigating the role of 
iron accumulation in hypoxic oligodendrocytes, the primary oligodendrocytes were 
split into four groups; control, hypoxia, control cells treated with deferoxmaine and 
hypoxic cells treated with deferoxmine  
2.4 Iron assay 
2.4.1 Materials Required 
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Iron assay kit (Biovision Inc; catalog #K 390-100) 
96 well plate (Nunc, Denmark) 
Microplate reader (Molecular devices, USA) 
2.4.2 Procedure for iron assay in vivo 
The PWM of rats at 3h, 24 h, 3d, 7d, and 14 d (n=3 at each time point) following 
hypoxic exposure and their corresponding age matched controls were dissected using a 
Leica stereo microscope. Tissue homogenates were prepared using protein extraction 
reagent as described under western blotting. Iron assay kit (BioVision; catalog #K 390-
100) was used to estimate the concentration of iron in the samples. This kit measures the 
Ferrous and/or Ferric ion in the sample. The acidity of the buffer enables the liberation 
of ferric ion into the solution from ferric carrier protein. The liberated ferric ion is 
reduced to ferrous form which in turn reacts with Ferene S, an iron chromogen, to form 
a stable colored complex which could be measured at 593nm. 
In brief, 50 µl of standards and samples were added to the 96 well plate. The 
volume was made up to 100 µl with the assay buffer provided. 5 µl of iron reducer was 
added and incubated for 30 min at room temperature. Subsequently, 100 µl of iron 
probe provided with the kit was added to all the wells and incubated for 60 min in dark, 
at room temperature. The color formed was read at 593nm in a precision microplate 
reader. The iron concentrations was calculated using the formula   
 
Concentration	of	iron	in	the	sample ൌ 	Sample	absorbance	obtained	from	standard	curveSample	volume	loaded 	
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2.4.3 Procedure for iron assay in vitro 
The concentrations of iron in control, hypoxic, and hypoxia + deferoxamine 
groups of primary microglial cultures and oligodendrocyte cultures were also 
determined using the same kit. After various treatments, the cultures were washed with 
PBS and the protein was extracted using mammalian protein extraction reagent as 
described under the section western blotting. The assay was performed as per 
manufacturer’s instructions as described above.  
2.5 Perls’ Iron staining 
2.5.1 Materials Required 
6% pentobarbital 
2% paraformaldehyde 
0.1M phosphate buffer (pH-7.4) 
10% potassium ferrocyanide 
10% hydrochloric acid 
1% hydrogen peroxide 
0.5% 3, 3’-diaminobenzidine 
0.01% nickel sulphate in phosphate buffer (PB) 
2.5.2 Procedure for iron staining in vivo 
Following the method described by Wang et al. (2002), Perls’ iron staining was 
performed in rat brains isolated at 3 d (n=3) after hypoxic exposure along with their 
corresponding controls. In brief, the rats were anesthetized with 6% sodium 
pentobarbital and perfused with 2% paraformaldehyde. From the brains isolated frozen 
sections of 40 µm thickness were cut using a cryostat (model 3050; Leica 
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Microsystems).  The sections were washed in PBS and incubated with Perls’ solution 
(1:2; 10% HCl and 10% potassium ferrocyanide) for 30 min at room temperature. 
Subsequently, the sections were rinsed in deionized water and immersed for 15 min in 
100ml of 0.005% 3, 3’-diaminobenzidine in PB containing 0.5 ml of 1% hydrogen 
peroxide as previously described by Hill and Switzer (1984). The sections were washed 
in distilled water for three times and then with PBS for three times with an interval of 5 
min. The sections were then incubated with markers for glial cells such as tomato 
(Lycopersicon esculentum) lectin (a marker for microglia), GFAP (a marker for 
astrocytes) and CC1 (a marker for oligodendrocytes). The sections were then rinsed in 
PBS and mounted using a fluorescent mounting medium (Dako). The staining was 
visualized under the confocal microscope (FV1000; Olympus Company Pte Ltd, Tokyo, 
Japan) 
2.5.3 Procedure for iron staining in vitro 
A modified Perls’ iron staining described by Dang et al. (2010) was performed 
on control, hypoxic, and hypoxia + deferoxamine group of primary microglial cultures. 
Immediately after the treatment, the cells were washed with PBS for three times and 
fixed with 4% paraformaldehyde for 30 min. The cells were washed with PB and then 
incubated with 5% potassium ferrocyanide solution containing 1.6 M HCl for 30 min. 
Subsequently, the cells were washed in PB for 20 min and then incubated in DAB-Ni 
sulphate solution prepared in PB containing 0.05% DAB, 0.01% nickel sulphate and 
0.0015% H2O2 for 30 min. The cells were then washed with PBS and incubated with 
FITC-conjugated lectin for 1 hour and the coverslip containing cells were mounted on 
to the glass slides using a fluorescent mounting medium (Dako). 
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2.6 Western Blotting 
2.6.1 Materials Required 
Bovine Serum Albumin (BSA) (Biorad, USA, Cat No. 500-0007) 
CL-Xposure film- clear blue film (Pierce, Thermo Scientific, USA ,Catalog # 34089) 
Mammalian protein extraction reagent (Pierce, USA Cat No. 78503) 
Mini transfer blot filter paper (BioRad, USA, Cat No. 1703932) 
Pico chemiluminescent substrate Kit (Pierce, Thermo Scientific, USA, Cat No.34080) 
Precision Plus Protein Standards Kaleidoscope (Bio-Rad, USA, Cat No. 161-0375) 
Protease inhibitor cocktail kit (Pierce, USA, Cat No. 78410) 
Protein assay kit (Bio-Rad, USA, Cat No. 5000002) 
Stripping buffer (Pierce, Thermo Scientific, USA, Cat No. 0021059) 
Tissue protein extraction reagent (Pierce, USA, Cat No. 78503) 
Equipment 
Densitometer (BioRad, USA, Model No. GS-710) 
Electrophoresis Unit (BioRad, USA) 
Film developer (Konica Minolta, Singapore; Model: SRX-101A) 
Gel-casting apparatus (BioRad, USA, Model : Mini PROTEAN) 
Power supply (BioRad, USA, Model: PowerPac HC) 
Quantity One software (BioRad, USA, ver 4.6.5) 
Semi dry transfer blot (BioRad, USA, Model: TransBlot SD) 
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10% Resolving gel 
Water                                                       4 ml 
30% acrylamide mix                               3.3 ml 
1.5M Tris (pH 8.8)                                  2.5 ml 
10% sodium dodecyl sulphate (SDS)     0.1 ml 
10% ammonium persulphate                  0.1 ml 
tetramethylethylenediamine (TEMED)  0.004 ml  
5% Stacking gel 
Water                                          5.5 ml 
30% acrylamide mix                  1.3 ml 
1.0 M Tris (pH 6.8)                    1.0 ml 
10% SDS                                    0.08 ml 
10% ammonium persulphate      0.08 ml 
TEMED                                      0.008 ml 
6x SDS gel loading buffer 
Tris Cl (pH 6.8) 50mM                  
Dithiothreitol  10mM                     
SDS 2% 
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Tris-glycine electrophoresis buffer 
Tris 25 mM 
Glycine 250 mM 
SDS 0.1% 
Transfer Buffer 
Tris 25 mM 
Glycine 250 mM 
Methanol 20% 
10X Tris buffered saline (TBS) 
Tris base 24.2g 
NaCl 80 g 
Volume made to 1 liter with water 
pH adjusted to 7.6 with 4N HCl 
1X Tris buffered saline tween (TBST) 
10X TBS             100ml 
ddH2O                 900 ml 
20% Tween 20    10 ml 
 
The primary and secondary antibodies used are listed in Table 2. Apart from the 
antibodies listed below, Lectin from tomato (Lycopersicon esculentum) was used as a 
marker for blood vessels and microglia 
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GFAP Chemicon  1:1000 
CC1 Calbiochem  1:20 
Proteins involved in iron regulation 
HIF-1α Abcam   




Proteins involved in iron transport 
TfR AbD Serotec for 
WB 
Abcam for IF 
1:200 1:100 
DMT-1 Santa Cruz 1:1000 1:100 
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FPN1 Abcam 1:1000 1:100 








MAPK signalling pathway 
p-ERK Cell signalling 
technologies 
1:2000 1:100 
p-P38 Cell signalling 
technologies 
1:500 1:100 
p-JNK Cell signalling 
technologies 
1:500  
p-CREB Cell signalling 
technologies 
1:1000  
MKP-1 Santa Cruz 1:200  
ER stress pathway 
RyR Santa Cruz 1:200 1:100 
Bip Cell signalling 
technologies 
1:1000  
IRE-1α Abcam 1:1000  
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P53 Cell signalling 
technologies 
1:500  
Caspase-3 Cell signalling 
technologies 
 1:100 








Goat 1:5000  
 
 
2.6.2 Dissection of PWM  
 The PWM tissue was carefully dissected from the rats with the help of a Leica 
stereo microscope (MZ6; Leica Pte Ltd, Singapore). The PWM tissues removed at 
different time points (3h, 24h, 3d, 7d and 14d) from rats subjected to hypoxia and their 
corresponding age matched controls (n=5 at each time point) were rinsed in PBS (to 
remove the blood stains) and snap frozen in liquid nitrogen. The samples were then 
stored at -80°C until use. 
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2.6.3 Protein extraction from tissue 
 The PWM tissue stored at -80°C was collected and then placed in an ice box. 
0.5ml of the tissue protein extraction reagent containing protease inhibitor and EDTA 
(1ml of tissue protein extraction reagent contains 10µl of 100X EDTA free protease 
inhibitor and 10µl of 100X EDTA) was added to each sample and allowed to react for 
10 min. After 10 min, tissues were homogenized using a tissue homogenizer. The 
samples were then centrifuged at 14000 rpm for 20 min at 4°C. The supernatant 
containing the protein was aliquoted and stored at -80° C until use.  
2.6.4 Total protein extraction from cells 
 For extracting protein from primary cultures, mammalian protein extraction 
reagent was used. The culture medium from the culture flasks was completely removed 
and washed with PBS once. 350µl of mammalian protein extraction reagent containing 
protease inhibitor and EDTA was added to the flask containing cells and allowed to 
react for 10 min. With the help of a cell scrapper, the cells were scrapped out and the 
contents were spinned at 14000 rpm for 20 min. The supernatant containing protein was 
stored at -80°C until use.   
2.6.5 Procedure 
2.6.5.1 Estimating Protein Concentration 
The concentrations of the protein samples extracted were measured using the 
method described by Bradford (1976) with bovine serum albumin (Sigma-Aldrich) as a 
standard. A serial dilution of BSA was carried out ranging from 0mg/ml to 1mg/ml. 
10µl of each sample or standard was pipetted into a 96 well plate. 200µl of diluted 
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protein assay dye was added and incubated for 15 min at room temperature. After 15 
min, the absorbance was measured at 595 nm with the help of a precision microplate 
reader (Molecular Devices). The protein concentration was calculated using the 
standard curve generated. 
2.6.5.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
 Aliquots of samples containing 40µg of protein, in the presence of 6X SDS gel 
loading buffer, were heated to 95°C for 5 min to denature the proteins. The proteins 
were then separated by the 10% or 6% SDS-PAGE in a Mini-Protean 2 apparatus (Bio-
Rad Laboratories) at 80 volts for 2-2.5 hours. The separated proteins were then 
electroblotted on to a 0.45µm polyvinylidene difluoride (PVDF) membrane (Bio-Rad) 
with the help of semi-dry electrophoretic transfer cell (Bio-Rad). Subsequently, the 
membranes were blocked with 5% non-fat dried milk powder for 1 hour at room 
temperature. The membranes were then washed for 10 min with 1X TBST, three times 
and were incubated with appropriate primary antibodies, overnight at 4°C in an orbital 
shaker. The list of primary antibodies used is provided in Table 3. The next day, the 
membranes were washed with 1X TBST for three times (each wash for 10 min) and 
were incubated at room temperature for 1 hour, with the respective secondary antibodies 
conjugated with horseradish peroxidase. Specific binding was revealed by enhanced 
chemiluminescence kit. The immunoreactive bands captured on the X-ray sheets were 
quantified using Densitometer and Quantity one software, version 4.4.1 (Bio-Rad). 
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2.7 Double Immunofluorescence Labelling 
2.7.1 Materials required 
Paraformaldehyde (Sigma) – 2% or 4% prepared in 0.1M phosphate buffer (pH 7.4) 
DAPI (Sigma, USA, Cat No D1306) 
PBS (10 X) (Invitrogen, USA, Cat No 142001166) 
Fluorescent mounting medium (DakoCytomation, Denmark, Cat No. S302380) 
The primary and secondary antibodies used for immunostaining are listed in Table 2 
and Table 3, respectively. 
Table 3: List of secondary antibodies used for double immunofluorescence 
Secondary Antibody Commercial source Dilution used 
Anti-Rabbit Cy3 Sigma-Aldrich 1:100 
Anti-Rabbit FITC Sigma-Aldrich 1:100 
Anti-Mouse Cy3 Sigma-Aldrich 1:100 
Anti-Mouse FITC Sigma-Aldrich 1:100 
 
2.7.2 Procedure for double immunofluorescence 
2.7.2.1 Double immunofluorescence in vivo 
 For cellular localisation of target proteins of interest, the rats were sacrificed at 
(n=3) following treatments along with their age matched controls. Rats anesthetized 
using 6% sodium pentobarbital were perfused with 2% paraformaldehyde. The fixed 
brains were removed and post-fixed for 4 hours. Following which the fixed brains were 
transferred to 0.1M PB containing 15% sucrose and placed at 4°C overnight. Frozen 
Materials and Methods 
66 
 
sections of the brain (40µm thick), were cut using a cryostat (Leica Microsystems). The 
sections were rinsed in PBS for three times with an interval of 5 min each. The sections 
were then blocked for endogenous peroxidase activity using 0.3% hydrogen peroxide in 
methanol for 30 min. The sections were rinsed in PBS for three times and were split into 
three groups.  
Sections in group 1 were incubated with the cocktail containing the glial marker 
[OX42 (microglial marker)/CC1 (oligodendrocyte marker)/GFAP (astrocyte marker)] 
and primary antibody against the target protein [IRP1/IRP2/DMT1/HIF-
1α/FPN1/Ceruloplasmin] at room temperature, overnight in a humidified chamber. The 
following day, the sections were rinsed in PBS and incubated with the respective 
FITC/CY3 conjugated secondary antibodies for 1 hour at room temperature.  
Sections in group 2 were used to study the changes in expression of proteins 
involved in iron transport in blood vessels. The sections were incubated with primary 
antibodies targeted against TfR, DMT1, FPN1 and ceruloplasmin, overnight at room 
temperature. Subsequently, the sections were washed in PBS and incubated with CY3 
conjugated secondary antibody. Following this, the sections were rinsed in PBS and 
incubated with Lectin (Lycopersicon esculentum) for 1 hour at room temperature.  
The sections in group 3 were used to study the expression of TfR in all three 
glial cells. To accomplish that, the sections were incubated with glial markers overnight 
and then subsequently with CY3 labelled secondary antibody. After this, the sections 
were washed in PBS and incubated with FITC conjugated TfR antibody (Abcam) for 1 
hour.  Finally, the sections were washed with PBS and mounted using a fluorescent 
Materials and Methods 
67 
 
mounting medium (Dako). Cellular localization was then examined under a confocal 
microscope (FV1000; Olympus Company Pte Ltd, Tokyo, Japan). 
 
2.7.2.2 Double immunofluorescence labelling in vitro 
 Immediately, after all the treatments, the cultured microglial cells were washed 
with PBS for three times with an interval of 5 min each and were fixed with 4% 
paraformaldehyde for 30 min. Following this, the cells were washed with PBS and 
blocked with 3% normal goat serum for 1 hour. Subsequently, the cells were incubated 
with cocktail of glial marker [OX42/CC1] and primary antibodies (listed in Table 3) 
overnight at 4°C. The following day, the cells were rinsed with PBS and incubated with 
respective FITC/CY3 conjugated secondary antibodies for 1 hour at room temperature. 
Finally after DAPI counterstaining, the coverslips containing cells were mounted onto 
glass slides using fluorescent mounting medium. The immunofluorescence staining was 
visualized under the confocal microscope (FV1000; Olympus Company Pte Ltd, Tokyo, 
Japan).   
2.8 Flow-cytometric analysis of reactive oxygen species 
2.8.1 Materials Required 
Fluoroprobe 5-(and 6)-choloromethyl-2’,7’-dicholoro-dihydrofluorescein diacetate 
(CMH2DCFDA) (catalog #C6827; Molecular Probes)  
10X trypsin EDTA 
1X PBS 
60 cm2 culture dish 
CyAn ADP Flow cytometer (Beckman coulter) 




CMH2DCFDA is a cell permeable ROS indicator. When CM-H2DCFDA enters 
the cell, it is cleaved by the esterases and a subsequent oxidation yields a fluorescent 
product. The purified microglia cells were split into control, hypoxic, and deferoxamine 
treated hypoxic microglial groups. The cultured microglial cells grown on 60 cm2 
culture dishes were detached by mild trypsinization (2X Trypsin-EDTA). The detached 
cells were washed with PBS to remove the traces of Trypsin-EDTA. Subsequently, the 
cells were resuspended in 0.5 ml of prewarmed PBS containing CM-H2DCFDA 
(10µM; diluted in DMSO) and incubated at 37°C for 60 min in the dark. Immediately 
after incubation, the cells were filtered through 60µm nylon mesh and subjected to 
flow-cytometric analysis (CyAn ADP; Beckman Coulter). The fluorescence intensity of 
2’,7’-dichlorofluorescein, the oxidized product of CMH2DCFDA was measured at an 
excitation of 488 nm and emission at 535 nm. The measured fluorescence intensity was 
considered to be directly proportional to the amount of ROS produced. The results were 
analysed with the summit software, version 4.3.  
2.9 Extracellular Reactive oxygen/nitrogen species assay 
Oxiselect in vitro ROS/RNS assay kit (catalog #STA-347; Cell Biolabs) was 
used to estimate the amount of ROS/RNS liberated by microglia. The conditioned 
medium derived from control, hypoxia, and deferoxamine treated hypoxic microglia 
was used to measure the total ROS/RNS levels released by these cells. In brief, 50µl of 
sample and DCF standard were added to wells of 96 well plate. To this, 50 µl of catalyst 
was added and incubated for 5 min at room temperature.  Then 100 µl of DCFH was 
added and incubated at room temperature for 45 min in dark. The fluorescence of the 
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samples and standards were read at 480 nm excitation/530 nm emissions using 
SpectraMaxM5 microplate reader (Molecular Devices). The 2’, 7’-
dichlorodihydrofluorescein standard curve generated following manufacturer’s 
instructions was used to calculate the concentration of total ROS/RNS liberated by 
microglia. 
2.10 ELISA 
2.10.1 Materials Required 
TNF-α ELISA kit (Cat No. BE45471; IBL International, Hamburg, Germany) 
IL-1β ELISA kit (Cat No. 27193; IBL International, Minneapolis, MN, USA) 
ELISA plate reader (Molecular Devices, USA) 
2.10.2 Procedure for TNF-α ELISA 
The concentration of TNF-α secreted into the conditioned medium by control, 
hypoxic and hypoxia + deferoxamine groups of microglial cultures was estimated using 
the rat TNF-α ELISA kit (Cat No. BE45471; IBL International, Hamburg, Germany) 
following manufacturers’ instructions. In brief, the conditioned medium from all three 
groups of microglial cultures was removed immediately after treatment. The wells to be 
incubated were brought to room temperature and washed with wash buffer. After 
ensuring complete removal of the wash buffer, 50µl of sample diluent was added to all 
wells followed by 50µl of samples/standards. Then, 50µl of freshly diluted biotin 
conjugated anti-rat TNF-α polyclonal antibody was added. The plate was sealed with an 
adhesive film and incubated at room temperature for 2 hours in a microplate shaker at 
300 rpm. Subsequently, the wells were washed with the wash buffer and incubated with 
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100µl of streptavidin-HRP solution for 1 hour at room temperature in a microplate 
shaker at 300 rpm. Following this the wells were washed and incubated with 100µl of 
TMB substrate solution for 10 min in dark. The color development was stopped by 
adding 100µ of stop solution into all the wells and was read at 450nm. The 
concentrations of TNF-α liberated were obtained from the standard curve generated 
2.10.3 Procedure for IL-1β ELISA 
The concentration of IL-1β in the conditioned medium of control, hypoxic and hypoxia 
+ deferoxamine group of microglial cultures was measured using rat IL-1β ELISA kit 
(Cat No. 27193; IBL International, Minneapolis, MN, USA) according to the 
manufacturer’s instructions. 100µl of samples and standards were pipetted into their 
respective wells and were incubated overnight at 4°C. The following day, the wells 
were washed with wash buffer for seven times.  After complete removal of wash buffer, 
the wells were incubated with 100µl of labelled antibody solution, at 4°C for 30 min. 
The wells were again washed with wash buffer for 9 times. Subsequently, 100µl of the 
chromogen solution was added to the wells and the reaction was allowed to occur for 30 
min in dark, at room temperature. The color development was stopped by adding 100µl 
of stop solution into the wells. The absorbance was read at 450nm. The concentration of 
IL-1β was calculated from the standard curve generated.    
2.11 Glutathione and Lipid peroxidation assay 
The effect of conditioned medium from microglia subjected to various 
treatments on glutathione content and lipid peroxidation in primary oligodendroyctes 
was assessed. For this, the primary cultured oligodendrocytes were divided based on 
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treatement as control (C) , cells treated with conditioned medium from control 
microglial cultures (CCM), cells treated with deferoxamine (DCM), hypoxia (H), cells 
treated with conditioned medium from hypoxic microglial cultures (HCM), and cells 
treated with conditioned medium from deferoxamine treated hypoxic microglial cultures 
(DHCM). The primary oligodendrocytes were treated for 4 hours, and immediately after 
the treatment, the protein were extracted from all of the above mentioned groups using 
mammalian protein extraction reagent containing protease inhibitors as described under 
western blotting.  
2.11.1 Procedure for glutathione assay.  
The glutathione content was measured using QuantiChrom Glutathione assay kit 
(DIGT-250; BioAssay Systems) according to manufacturer’s instruction. Blank and 
calibrator wells were added with 100µl of water and 100µl of calibrator respectively. 
Then, 200µl of water was added. For samples, equal volume of sample and reagent A 
was mixed in a centrifuge tube. In case of turbidity, the samples were spinned down at 
14000 rpm for 5 min and 200µl of the supernatant was added to the wells. 
Subsequently, 100µl of reagent B was added to each well and the 96 well plate 
containing the samples was incubated at room temperature for 25 min. The absorbance 
was read at 412 nm using a precision microplate reader (Molecular Devices). The 
concentration of glutathione was calculated from the optical density of samples and 
calibrator using the formula 
glutathione	concentration	in	sample	
ൌ optical	density	of	sample െ optical	density	of	blankoptical	density	of	calibrator െ optical	density	of	blank 	X	100	ሺμMሻ 
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2.11.2 Procedure for lipid peroxidation assay 
The quantification of lipid peroxidation in all six groups of oligodendrocytes 
was done using the lipid peroxidation colorimetric assay kit, BioAssay (catalog #2496-
30; US Biological) following the manufacturer’s instructions. This kit measures the 
malondialdehyde (MDA) in combination with 4-hydroxyalkenals generated by 
polyunsaturated fatty acid peroxides upon decomposition. In 1.5 ml centrifuge tube 
200µl of sample was added followed by 650µl of diluted R1 reagent. The contents of 
the centrifuge tube were mixed gently by vortexing. To this mixture, 150µl of R2 
reagent was added and the mixture was maintained at 45°C for 60 min. The samples 
were then spinned at 15,000g for 10 min and the supernatant was used to measure the 
absorbance at 586 nm. The concentration of lipid peroxidation end product MDA, in all 
the samples was calculated using the MDA standard curve obtained.  
2.12 Caspase-3 Labelling 
Caspase-3 labelling was done to study if TNF-α secreted by microglia could 
cause damage to the oligodendrocytes. To accomplish that, initially, control 
oligodendrocytes were exposed to recombinant rat TNF-α (100 ng/ml; Millipore 
Bioscience Research Reagents; catalog #GF046) (Yeh et al., 2000) and caspase-3 
labelling was performed. To study if TNF-α in the microglial conditioned medium 
induced cleavage of caspase-3, the primary oligodendrocytes were divided into six 
groups based on their treatment as: control; cells treated with conditioned medium from 
control microglial cultures; cells treated with deferoxamine; cells treated with 
conditioned medium from hypoxic microglial cultures; cells treated with conditioned 
medium from deferoxamine treated hypoxic microglial cultures; cells treated with 
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medium from hypoxic microglial cells neutralized with anti-TNF-α (10 µg/ml; 
Millipore Bioscience Research Reagents) (Sivakumar et al., 2011). Immediately after 
subjecting oligodendrocytes to various treatments for 4 h, the cells were fixed in 4% 
paraformaldehyde for 30 min. The fixed cells were blocked with 3% normal goat serum 
for 1 hour and then incubated with cocktail of primary antibodies directed against 
cleaved caspase-3 (1:200; Cell Signaling Technology) and CC1 overnight at 4°C. The 
next morning, the cells were washed with PBS and incubated with respective FITC/CY3 
conjugated secondary antibodies and processed as described above under the section on 
double immunofluorescence. 
2.13 Proliferation assay 
The effect of IL-1β secreted by microglia on the proliferation of 
oligodendrocytes was assessed using the Quick Cell Proliferation assay kit (Abcam; 
catalog #ab65473) according to the manufacturer’s instructions. The primary 
oligodendrocytes grown in 96 well plates were divided into 7 groups based on the 
treatment. Group 1 cells served as control; Group 2 cells were treated with conditioned 
medium from control microglial cultures; Group 3 cells were treated with 
deferoxamine; Group 4 cells were treated with IL-1β peptide (100 pg/ml; IBL; catalog 
#27193), as described previously (Palmer et al., 1995), and was neutralized with anti-
IL-1β (10 µg/ml; Millipore Bioscience Research Reagents); Group 5 cells were treated 
with conditioned medium from hypoxic microglial cultures; Group 6 cells were treated 
with conditioned medium from deferoxamine treated hypoxic microglial cultures; 
Group 7 cells were treated with medium from hypoxic microglial cells containing anti-
IL-1β (10 µg/ ml; Millipore Bioscience Research Reagents). After 4 hours of treatment, 
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10µl of the tetrazolium salt, WST-1 reconstituted in electro coupling solution was added 
to each well and the 96 well plates were returned to incubator with standard culture 
conditions. Four hours later, the optical density was measured at 440 nm using 
SpectraMaxM5 microplate reader (Molecular Devices).  The results were expressed as 
percentage inhibition of proliferation with respect to control cells. For neutralization 
studies, the concentration of anti-IL-1β was determined based on the cell viability assay 
performed, in which there was increased viability of oligodendrocytes at a concentration 
of 10 µg/ml of anti-IL-1β (data not shown). 
2.14 Terminal deoxynucleotidyl transferase (Tdt)-mediated dUTP nick end 
labeling (TUNEL) assay  
The apoptosis of oligodendrocytes when treated with conditioned medium from 
microglia was assessed using an In situ Cell Death Detection kit (Cat No. 11 684 795 
910; Roche Diagnostics). The primary oligodendrocytes were split based on their 
treatment as control (C), control + conditioned medium from control microglial cells 
(CCM), control + deferoxamine (DCM), hypoxia (H), control + conditioned medium 
from hypoxic microglia (HCM), control + conditioned medium from deferoxamine 
treated hypoxic microglial cells (DHCM). Immediately after 4 hours of treatment, the 
cells were washed in PBS for three times and fixed with 4% paraformaldehyde for 60 
min at room temperature. The cells were then rinsed in PBS and permeabilized with 
0.1% TritonX-100 prepared in 0.1% sodium citrate for 2 min on ice. Subsequently the 
cells were rinsed with PBS and 50µl of TUNEL reaction mixture was added and was 
incubated at 37°C for 60 min in dark. Following this, the cells were rinsed in PBS for 
three times and incubated with CC1 antibody (1:20; a marker for oligodendrocytes) 
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overnight at 4°C. Subsequently, the cells were incubated with CY3-conjugated anti-
mouse IgG secondary antibody for 1 hour at room temperature. This was followed by 
staining of cell nucleus with DAPI. The cells were then mounted on to glass slides using 
a fluorescent mounting medium (Dako). The TUNEL labelling was observed under the 
confocal microscope (FV1000). Images from 8 random microscopic fields were 
captured for each slide at 40X magnification by a blinded observer from which the total 
number of TUNEL positive cells was calculated. The percentage of TUNEL-positive 
oligodendrocytes against the total number of oligodendrocytes was calculated and 
averaged. 
2.15 Electron microscopy in vitro 
 The ultrastructural changes of endoplasmic reticulum in the control, hypoxic and 
deferoxamine treated hypoxic oligodendrocytes were studied using transmission 
electron microscopy. The purified oligodendrocytes were seeded in a LabTekTM 4-well 
chambered coverglass (Thermo scientific, Nunc; Catalog No.155382) and subjected to 
various treatments. Immediately after the treatment the cells were washed for three 
times with PBS with an interval of 5 min each, and then fixed for 1 hour with 2.5% 
glutaraldehyde. The fixed cells were then washed with PBS for three times and were 
post fixed in 1% osmium tetroxide for 1 hour. The cells were then dehydrated in a series 
of increasing ethanol concentrations and gradually infiltrated with increasing 
concentrations of araldite. The infiltration was initially done with a mixture of ethanol 
and araldite in the ration of 1:1, followed by a ratio of 1:4, for 30 minutes each. 
Subsequently the samples were infiltrated with 3 changes of 100% araldite and 
incubated at varying temperatures from 45°C to 55°C for 45 minutes each. Finally, the 
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samples were embedded in fresh araldite resin and incubated at 60°C for 24 hours to 
enable the polymerisation of resin. After this, the coverglass was removed and the 
polymerized resin containing the monolayer of cells was used to cut ultrathin sections 
(<100nm thick) with the help of an ultra-microtome. The ultrathin sections were picked 
up on copper grids and stained with uranyl acetate and lead citrate to improve its 
viewing under electron microscope. The sections were observed under a Joel JEM 1220 
electron microscope.  
2.16 Statistical Analysis 
The data were presented as mean േ	 standard deviation (SD). Statistical 
significance of differences between the groups was calculated using paired Student’s t 
test. Statistical significance between the groups with respect to control was represented 
as *p < 0.05 and **p < 0.01 and with respect to cells exposed to hypoxia/hypoxic 
conditioned medium, statistical significance was represented as #p < 0.05 and ##p < 
0.01. 
The mean and SD were calculated using the formulae 
ܯ݁ܽ݊ ൌ ∑ݔ݊  
ܵܦ ൌ ඨ∑ݔ
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3.1 Composition of PWM 
The periventricular white matter (PWM) located peripheral to the lateral 
ventricles (V) is seen in the light microscopic image of brain sections stained with 
methyl green (within dotted triangle) (Fig 1. A). The PWM in the developing brain 
consists of unmyelinated axons, blood vessels (Fig 1. B) and AMCs (Fig 1. B,C), 
astrocytes (Fig 1. D) and oligodendrocytes (Fig 1. E). 
3.2 Hypoxia induced excess iron levels in PWM 
The bar graph (Fig 2) shows the changes in iron concentration in PWM of rats 
killed at 3h, 24h, 3d, 7d and 14 d following hypoxic exposure along with their 
corresponding controls. Iron levels were significantly increased from 3h to 7 d in 
hypoxic rats (Fig 2), when compared to their controls. There was a significant decrease 
in iron levels at 14d following hypoxic exposure when compared to control.    
3.2.1 Expression of proteins involved in iron metabolism in hypoxic PWMD 
The changes in expression of proteins IRP1, IRP2 and HIF-1α (Fig 3.A), which 
are involved in regulation of iron metabolism, were studied by western blotting. 
Immunoreactive band for IRP1 appeared at 97 kDa. The protein expression of IRP1 (Fig 
3B) was up-regulated significantly at 3d and 7d following hypoxia and significantly 
down-regulated at 14d after hypoxic exposure in comparison to the control group. The 
immunoreactive band for IRP2 appeared at 105 kDa and the expression of IRP2 (Fig 
3C) was enhanced significantly at 24h, 3, 7 and 14d following hypoxic exposure when 




and was found to increase in density (Fig 3D) at 3, 24h, 3 and 7d after hypoxic 
exposure. 
Western blotting of proteins involved in iron transport such as the TfR, DMT1, 
FPN1 and CP (Fig 4.A) showed a significant difference in their expression in hypoxic 
PWM. The immunoreactive bands for TfR (Fig 4 B), and DMT1 (Fig 4 C) appeared at 
95 kDa and 68 kDa respectively. The protein expression of TfR was up-regulated 
significantly at all time-points from 3h to 14 d in hypoxic PWM. When compared to 
control, the expression of DMT1 was increased at 3, 24h, 3 and 7d after hypoxic 
exposure and was significantly down-regulated at 14 d after hypoxia. The 
immunoreactive band for FPN1 (Fig 4 D) appeared at 63 kDa and was found to be 
increased at 24h and 3d following hypoxic exposure. The immunoreactive band for CP 
(Fig 4 E) appeared at 130 kDa and was found to be significantly enhanced in density 
only at 3d after hypoxic exposure.       
3.2.2 Expression of iron transport proteins in the endothelial cells of PWM 
In PWM of rats killed at 3d, following hypoxic exposure, the expression of TfR 
and DMT1 (Fig 5. A, B (a-f)), in lectin labelled blood vessels, was found to be 
enhanced when compared to that of control. There was no significant change in the 
expression of FPN1 and CP (Fig 6. A, B (a-f)) in blood vessels between hypoxic and 
control groups. The expression of TfR, DMT1, FPN1 and CP was also found in lectin 
labelled AMCs (Fig 5,6). 




In the developing PWM of rats killed at 3d following hypoxic exposure, the 
presence of iron positive cells was revealed by Perls’ iron staining (Fig 7 A). With the 
help of markers such as lectin, GFAP and CC1 the type of glial cells accumulating iron 
was identified. Majority of the iron positive cells were found to be the AMCs (Fig 7 B).  
AMCs of hypoxic PWM stained intensely for iron when compared to that of control and 
the number of iron positive microglial cells were also increased in comparison to 
control sections. The astrocytes, marked by GFAP, were not found to be iron positive 
(Fig 8A) whereas their processes were found to overlap with iron positive cells in the 
hypoxic PWM. There were few CC1 positive oligodendrocytes that were faintly stained 
for iron (Fig 8B) following hypoxic exposure.   
3.4 Cellular distribution of proteins involved in iron metabolism 
In PWM of rats killed at 3 d following hypoxic exposure the distribution and 
expression of proteins involved in iron metabolism such as HIF-1α, IRP1, IRP2, TfR, 
DMT1, FPN1 and CP were studied in the glial cells using double immunofluorescence. 
3.4.1 Amoeboid Microglial Cells 
In response to hypoxic exposure, the expression of proteins HIF-1α, IRP1 and 
IRP2, involved in iron regulation, were upregulated in the AMCs of PWM (Fig 9A-C 
(a-f)). The expression of TfR and DMT1 (Fig 10A, B (a-f)) which are involved in iron 
uptake was also found to be up-regulated in AMCs of hypoxic PWM when compared to 
control sections. On the contrary, in comparison to control, the expression of FPN1 and 





In response to hypoxic exposure, the expression of HIF-1α (Fig 12 A) was found 
to be increased in astrocytes in comparison to control group, whereas the expression of 
IRP1 (Fig 12 B) and IRP2 (Fig 12 C) was not significantly altered. The protein 
expression of TfR, DMT1, FPN1 and CP (Fig 13, 14A, B (a-f)) was increased 
significantly in astrocytes of hypoxic PWM when compared to that of control group.  
3.4.3 Oligodendrocytes 
Following hypoxic exposure, the expression of HIF-1α, IRP1 and IRP2 (Fig 15 
A-C(a-f)) was found to be up-regulated in CC1 labelled oligodendrocytes when 
compared to that of control. Among the proteins involved in iron transport, only TfR 
expression (Fig 16 A(a-f)) was found to be enhanced in oligodendrocytes of hypoxic 
PWM when compared to control group. The expression of DMT1 (Fig 16 B(a-f)) was 
not detected in both hypoxic and control oligodendrocytes. The expression of FPN1 
(Fig  17 A(a-f)) and CP (Fig 17 B(a-f))  was found to be unaltered between control and 
hypoxic groups.  
3.5 Hypoxia induced iron accumulation in microglial cultures 
The iron content of microglial cultures was increased when subjected to hypoxia 
and this increase was significant when compared to that of control microglia (Fig 18). 
However, the increased iron levels were brought back to control levels on treating 
hypoxic microglial cells with deferoxamine. Perls’ iron staining on microglial cultures 
(Fig 19 A) also showed an increase in iron content in hypoxic microglia. In addition, the 
percentage of Perls’ iron positive microglial cells in hypoxic group was significantly 




effectively reduced the occurrence of Perls’ positive microglia in hypoxic microglial 
cultures when compared with hypoxic microglial cultures not treated with deferoxamine  
3.6 Mechanism of iron regulation in hypoxic microglial cultures 
Similar to the in vivo data, in comparison to control cultures, double 
immunolabelling indicated an up-regulation in the expression of proteins HIF-1α, IRP1 
and IRP2 (Fig 20 A-C(a-f)) in hypoxic microglial cultures.  
3.6.1 HIF-1α in regulating iron uptake process in microglial cultures  
The changes in expression of HIF-1α, TfR and DMT1 (Fig 21 A) in microglial 
cells, when subjected to varying duration of hypoxia, were analysed using western 
blotting. Immunoreactive band for HIF-1α appeared at 110 kDa. There was a significant 
increase in the protein expression of HIF-1α (Fig 21 B) in microglia exposed to hypoxia 
for 2h to 6h, when compared to that of control. The immunoreactive band for TfR 
appeared at 95 kDa. The protein expression of TfR (Fig 21 C) was found to be 
significantly increased in microglial cells exposed to 4 h of hypoxia. At 68 kDa, the 
immunoreactive band for DMT1 appeared. Similar to that of TfR, expression of DMT1 
(Fig 21 D) was up-regulated in microglia exposed to 4h of hypoxia. 
The regulation exhibited by HIF-1α on the expression of TfR and DMT1 in 
hypoxic microglial cells was studied by western blotting. The immunoreactive bands for 
TfR and DMT1 (Fig 22 A) appeared at 95kDa and 68 kDa respectively. The expression 
of TfR and DMT1 (Fig 22 B-C) was enhanced in microglial cells following a hypoxic 
exposure for 4h. However, KC7F2 suppressed the increased expression of TfR and 




3.6.2 IRPs in mediating iron uptake in hypoxic microglial cells 
The immunoreactive bands for IRP1 and IRP2 (Fig 23 A) appeared at 97 and 
105 kDa. At the end of 4h of hypoxic exposure, as showed by western blotting, the 
expression of IRP1 and IRP2 (Fig 23 B, C) was significantly increased in hypoxic 
microglia when compared to control microglia 
3.7 Role of increased iron accumulation in hypoxic microglia 
3.7.1 Iron increases intracellular ROS production in microglia 
Iron enhances intracellular ROS production in microglia (Fig 24 A). On 
exposing microglial cells to 4h of hypoxia the generation of ROS was increased by ~ 
30% in comparison to control microglia. However, in hypoxic microglia treated with 
deferoxamine the generation of ROS was reduced by ~20% when compared to hypoxic 
cells not treated with deferoxamine.  
 3.7.2 Extracellular ROS/RNS released by microglia in response to iron 
accumulation 
The amount of total ROS/RNS released in to the culture medium by hypoxic 
microglial cells was significantly increased (Fig. 24 B) at the end of 4h of hypoxia, 
when compared with that of control microglia. However, on treating with deferoxamine 
the amount of ROS/RNS secreted by hypoxic microglia was significantly decreased 
when compared to the hypoxic microglia not treated with deferoxamine.  
3.7.3 Iron enhances cytokine production in microglia and in PWM 
The role of iron in inducing cytokines production by hypoxic microglia was 




TNF-α (Fig 25 A) and IL-1β (Fig 26 A) was found to be increased in hypoxic microglia 
when compared to that of control. This increase was however attenuated when hypoxic 
microglia were treated with deferoxamine. The levels of TNF-α (Fig 25 B) and IL-1β 
(Fig 26 B) secreted by microglia into the conditioned medium was estimated. In 
response to hypoxic exposure there was significant increase in the release of TNF-α and 
IL-1β by microglia. Interestingly when compared to hypoxic microglia not treated with 
deferoxamine, the increase in pro-inflammatory cytokines was significantly suppressed 
on treating hypoxic microglia with deferoxamine.  
3.8 Iron accumulation in hypoxic microglia induces oligodendrocyte death 
3.8.1 Effect of microglial conditioned medium on glutathione levels in 
oligodendrocytes 
In primary oligodendrocyte cultures the changes in glutathione levels on 
treatment with conditioned medium from various groups of microglia were estimated. In 
hypoxic oligodendrocytes the concentrations of glutathione dropped significantly when 
compared to that of control oligodendrocytes (Fig 27A). Similarly the glutathione level 
was significantly decreased in oligodendrocytes subjected to treatment with conditioned 
medium from hypoxic microglial cells when compared with that of control group. 
However, when oligodendrocytes were treated with conditioned medium from 
deferoxamine treated hypoxic microglia the glutathione concentration was significantly 
increased in comparison to hypoxic oligodendrocytes and those treated with medium 




3.8.2 Effect of microglial conditioned medium on lipid peroxidation in 
oligodendrocytes 
The lipid peroxidation levels as manifested by MDA concentrations were 
measured in oligodendrocytes subjected to various treatments. When compared to the 
MDA concentration in control oligodendrocytes there was a significant increase in 
MDA concentrations (Fig 27 B) in oligodendrocytes subjected to either hypoxia or 
treated with medium derived from hypoxic microglial cells. However, in comparison to 
hypoxic oligodendrocytes, MDA concentrations significantly decreased when the 
oligodendrocytes were treated with medium from deferoxamine treated hypoxic 
microglia.  
3.8.3 IL-1β on proliferation of oligodendrocytes 
In oligodendrocytes treated with conditioned medium from hypoxic microglial 
cells the proliferation of oligodendrocytes was inhibited by ~ 15%. On the contrary, on 
subjecting the oligodendrocytes to treatment with medium derived from deferoxamine 
treated hypoxic microglia the inhibition of proliferation observed was negligible (Fig 
28). Remarkably, the inhibition of proliferation of oligodendrocytes observed when 
treated with medium from hypoxic microglia, was significantly reduced when treated 
with medium from hypoxic microglia neutralized for IL-1β.  
3.8.4 Caspase-3 activation in oligodendrocytes by TNF-α 
Oligodendrocytes on treatment with exogenous TNF-α showed increased 
caspase-3 labelling, indicating that TNF-α could cause the death of oligodendrocytes 




was examined by treating primary oligodendrocytes with conditioned medium from 
control, hypoxic and hypoxia + deferoxamine  microglial groups (Fig 29 B-D). In 
control oligodendrocytes and oligodendrocytes treated with either conditioned medium 
from control microglia or deferoxamine, only few cells were positive for caspase-3. On 
subjecting the oligodendrocytes to treatment with conditioned medium from hypoxic 
microglia there was increased caspase-3 immunolabelling.  In comparison to 
oligodendrocytes treated with conditioned medium from hypoxic microglia there was a 
significant reduction in caspase-3 labelling in oligodendrocytes treated with medium 
from hypoxia+deferoxamine microglial cultures or from hypoxic microglia neutralized 
with TNF-α antiserum. In oligodendrocytes treated with medium from hypoxic 
microglia there was a significant increase in the percentage of caspase-3 positive 
oligodendrocytes (Fig 29 E). However, this increase was reversed when treated with 
medium from deferoxamine treated hypoxic microglial cells or with medium neutralized 
from TNF-α. 
3.8.5 Factors released due to iron accumulation in hypoxic microglia induce 
apoptosis of oligodendrocytes 
In primary oligodendrocytes, TUNEL assay was performed to examine their 
apoptosis following hypoxic exposure and on treatment with conditioned medium from 
control, hypoxic and deferoxamine treated hypoxic microglia (Fig 30 A-C). In control 
oligodendrocytes and in cells treated with medium from control microglia or with 
deferoxamine there was very few TUNEL positive cells. When oligodendrocytes were 
subjected to hypoxic exposure or on treatment with medium derived from hypoxic 




D). However, this increase was significantly reverted to control levels when 
oligodendrocytes were treated with medium derived from deferoxamine treated hypoxic 
microglia. 
3.9 Iron promotes MMP-9 secretion in microglia 
The increased iron within AMCs in the hypoxic PWM resulted in the increased 
production of MMP-9. When compared to control group, the intensity of MMP-9 was 
enhanced in AMCs (Fig 31 a-i) of hypoxic PWM. However, in PWM of deferoxamine 
treated hypoxic rats, there was reduced expression of MMP-9, suggesting a role for iron 
in the production of MMP-9 by hypoxic AMCs.  
3.10 Deferoxamine and KC7F2 involves MAPK pathway 
3.10.1 Differential expression of MAP kinases  
The changes in the expression of MAP kinases in hypoxic microglia and on 
treatment with deferoxamine/KC7F2 were studied using western blotting. The 
immunoreactive bands for p-ERK, p-P38 and p-JNK appeared at 44/42 kDa, 43kDa, 
46/54 kDa (Fig 32 A) respectively. In hypoxic microglia the expression of all three 
MAP kinases (p-ERK, p-P38 and p-JNK) was up-regulated. But on treating hypoxic 
microglial cells with either deferoxamine or KC7F2 there was a differential expression 
in all three MAP kinases. The hypoxia induced p-ERK (Fig 32 B) expression was 
further up-regulated significantly on treatment with deferoxamine/KC7F2. On the 
contrary, the expression of p-P38 (Fig 32 C) enhanced in response to hypoxia was 
down-regulated significantly on treatment with deferoxamine/KC7F2. However the 




Double immunofluorescence analysis of p-ERK (Fig 33 a-i) and p-P38 (Fig 34 
a-i) was performed in control, hypoxic and deferoxamine treated hypoxic microglial 
cultures. The fluorescence intensity of p-ERK was significantly enhanced in hypoxic 
microglia treated with deferoxamine in comparison to that observed in hypoxic 
microglia, whereas, that of p-P38 was reduced in deferoxmaine treated hypoxic 
microglia.  
3.10.2 p-ERK mediates p-CREB up-regulation 
The role of p-ERK in mediating CREB activation was studied with the help of 
U0126 on hypoxic microglia. The immunoreactive band for p-CREB (Fig 35 A) 
appeared at 43kDa. In hypoxic microglial cells the expression of p-CREB was 
significantly up-regulated in comparison to that of control. When compared to hypoxic 
microglial cells, in deferoxamine or KC7F2 treated hypoxic microglia, the expression of 
p-CREB (Fig 35 B) was up-regulated similar to p-ERK. Interestingly, on treating 
hypoxic microglial cells with U0126 (inhibitor for p-ERK) there was a significant 
down-regulation in the expression of p-CREB.  
3.10.3 p-ERK may induce MKP1 upregulation  
Up-regulation of p-ERK may induce MKP1, which sets up the negative feedback loop 
to dephosphorylate the MAP kinases. Immunoreactive band for MKP-1 (Fig 35 A) 
occurred at 40 kDa. The expression of MKP-1 (Fig 35 C) was significantly enhanced in 
response to hypoxia when compared to control microglial cells In microglia cells 
subjected to hypoxia and treated with KC7F2 the expression of MKP-1 remained 




microglial cells treated with deferoxamine, expression of MKP1 was further enhanced 
significantly when compared to hypoxic microglia not treated with deferoxamine. In 
hypoxic cells treated with U0126, the MKP1 levels were similar to that observed in 
hypoxic microglial cells.  
3.10.4 P38 activation leads to cytokines production 
Western blot analysis of the cytokines TNF-α and IL-1β (Fig 36 A) revealed the 
significant increase in their protein concentrations in hypoxic microglia. However, on 
treatment with either deferoxamine or SB202190 (P38 inhibitor) or SP600125 (JNK 
inhibitor) the expression of TNF-α (Fig 36 B) and IL-1β (Fig 36 C) was significantly 
reduced in hypoxic microglia. Though KC7F2 decreased the expression of TNF-α in 
hypoxic microglial cells it was non-significant, whereas, KC7F2 resulted in significant 
reduction in IL-1β levels in hypoxic microglia.   
3.11 Iron accumulation in oligodendrocytes 
The changes in iron content in control, hypoxic and hypoxia+deferoxmaine 
group of primary oligodendrocytes were estimated. In oligodendrocytes subjected to 
hypoxia there was significant increase in their iron levels (Fig 37 A) when compared to 
the control cells. However, this increase was brought back to control levels when treated 
with deferoxamine. 
3.12 Iron induced morphological changes in the endoplasmic reticulum of 
oligodendrocytes 
Electron microscopic study revealed a significant difference in the morphology 




was highly dilated when compared to the ER visualised in the control cells (Fig 37 B). 
When these hypoxic oligodendrocytes were treated with deferoxamine, the dilation 
observed in ER was reduced. The dilation of ER indicates that hypoxia induces ER 
stress in oligodendrocytes which could have been mediated by iron.  
3.12.1 RyR expression co-localized to hypoxic oligodendrocytes 
 By means of western blotting RyR expression was found to be significantly 
increased in the PWM of hypoxic rats (Fig 38 A). Immunoreactive band for RyR 
appeared at 550 kDa and was found to be significantly up-regulated from 3d to 14d (Fig 
38 B). The same was confirmed by immunofluorescence. In the PWM, in response to 
hypoxia enhanced expression of RyR was observed in the CC1 labelled 
oligodendrocytes (Fig 38 C) when compared to the control group.  
3.12.2 Iron induced markers of ER stress in hypoxic oligodendrocytes 
 By means of western blotting, ER stress markers such as RyR, Bip, IRE-1α and 
PERK was analysed in control, control + deferoxamine, hypoxic and deferoxamine 
treated hypoxic oligodendrocytes. The immunoreactive band for RyR, Bip and IRE-1α 
appeared at 550 kDa, 75 kDa and 110 kDa respectively (Fig 39 A).  The protein 
expression of RyR (Fig 39 B), Bip (Fig 39 C), IRE-1α (Fig 39 D) was up-regulated at 
the end of 4 hours of hypoxic exposure. When treated with deferoxmaine the enhanced 
expression of RyR, Bip, and IRE-1α was decreased significantly suggesting that the 
expression of these proteins could be due to the iron induced ER stress. The protein 




exposed to 4h of hypoxia and when treated with deferoxamine it was significantly up-
regulated. 
3.12.3 Iron induced apoptosis of oligodendrocytes through p53 
The immunoreactive band for p53 appeared at 50 kDa (Fig 39 A). In response to 
hypoxia the expression of p53 was up-regulated significantly in oligodendrocytes (Fig 
39 F) when compared to the control cells. However, on treatment with deferoxamine the 
increased expression of p53 was suppresed in hypoxic oligodendrocytes. 
Immunofluorescence analysis of caspase-3 showed an increase in caspase-3 labelling in 

























PWMD is a hallmark injury induced by hypoxia in preterm infants and is the 
leading cause of mortality and neurological impairments in these infants (Volpe, 2000; 
Ferriero, 2004).  Hypoxia induced PWMD is characterised by selective loss of 
oligodendrocytes, astrogliosis, microglial activation, and axonal swelling (Skoff et al., 
2001; Folkerth, 2006; Haynes et al., 2008). In view of the complex interplay of several 
mediators in causing hypoxic PWMD, a complete understanding of the mechanisms 
involved in the pathogenesis is still not available.  The fact that the immature brain is 
rich in iron (Ferriero, 2001) and the findings that 1) free radical induced oxidative stress 
plays a vital role in the pathogenesis of PWMD (Haynes et al., 2003), 2) ferritin positive 
cells are present in developing human white matter as early as 25 weeks of gestation 
(Ozawa et al., 1994), and 3) the presence of non-protein bound iron in the CSF of 
preterm infants suffering from intraventricular haemorrhage (Savman et al., 2001) 
suggest that excess iron could play a role in PWMD (Khwaja and Volpe, 2008).  
4.1 Iron accumulates in hypoxic PWM 
Increased iron accumulation in the brain is a common finding in 
neurodegenerative diseases (Ke and Qian, 2007).  Studies on animal models of ischemia 
have also reported brain iron overload in response to middle cerebral artery occlusion in 
these models (Castellanos et al., 2002; Yang et al., 2011). In PWM of ischemic-anoxic 
children, Dietrich showed the accumulation of iron by using MRI (Dietrich and Bradley, 
1988). By micro-dialysis, non-protein bound iron was found to be increased in the 
PWM of piglets in response to hypoxia (Savman et al., 2005). Consistent with these 
findings, in the present study, in response to hypoxia, the concentration of iron was 




that contributes to this increase of iron in PWM remained to be unravelled (Lin et al., 
2013). The increase in iron levels in the hypoxic PWM could have been favoured by the 
endothelial cells of blood vessels in PWM. As stated under the section-“Iron uptake into 
the brain” iron transport into the brain from the blood is via TfR expressed on the brain 
capillaries. In response to hypoxia, TfR and DMT1 expression was upregulated in the 
endothelial cells of PWM suggesting an increased iron uptake from the plasma, which 
could be later released into the PWM via the iron efflux channels expressed on the 
abluminal surface of the endothelial cells.     
4.1.1 Iron regulation in the hypoxic PWM tissue 
Hypoxia is known to enhance the iron uptake of a cell and the expression of 
HIF-1α, a transcription factor stabilized in response to hypoxia. In addition, hypoxia is 
known to favour the transcription of a series of genes including those involved in iron 
metabolism (Ke and Costa, 2006).  The up-regulation of HIF-1α in the hypoxic PWM 
could result in increased expression of iron transport proteins such as TfR, DMT1, 
FPN1 and CP which are hypoxia inducible (Tacchini et al., 1999; Mukhopadhyay et al., 
2000; Martin et al., 2005; Qian et al., 2011). Additionally, iron homeostasis is 
established at cytosolic level by the presence of IRPs (IRP1 and IRP2) in the cells and 
they do this by altering the expression of iron transport proteins by binding to their 
mRNAs. The unique IRP/IRE interaction switch enabled by the changes in iron levels in 
a cell is essential for maintaining the concentration of iron that is harmless to the cell. 
Dysregulation of these IRPs have been implicated in the pathogenesis of various 
neurodegenerative diseases (Cairo et al., 2002). For example dysregulation in the 




Connor, 2000). In the hypoxic PWM, the expression of IRP1 and IRP2 was enhanced. It 
is possible that this enhanced expression of IRPs could cause a dysregulation in iron 
metabolism by altering the expression of proteins involved in iron transport in hypoxic 
PWM.  
4.1.2 Iron transport proteins in the hypoxic PWM tissue 
The dysregulation in the expression of proteins TfR, DMT1 and FPN1 has been 
previosuly suggested to be the major cause of iron accumulation in ischemic brains 
(Qian and Shen, 2001; Castellanos et al., 2002).  In the hypoxic PWM, the expression of 
TfR and DMT1 was increased until 7d following hypoxic exposure indicating an 
increased iron up-take. While the iron efflux protein FPN1 was found to be up-regulated 
at early time points, it was down-regulated at later time points. This indicates that the 
iron efflux mechanism is impaired in hypoxic PWM. Associated with this there was 
reduced expression of CP at later time points in the hypoxic PWM.  Increased 
expression of TfR and DMT1 and reduced expression of FPN1 has been demonstrated 
to contribute to ischemia-induced brain iron accumulation (Yang et al., 2011).  
4.2 Cellular localization of iron in the hypoxic PWM  
In the event of hypoxia-ischemia, iron laden microglial cells were previously 
demonstrated in the developing rodent brains (Palmer et al., 1999). In response to 
hypoxic-ischemic insults presence of iron positive cells were reported in the developing 
white matter and based on the structural characteristics these cells were reported to be 
microglial cells (Cheepsunthorn et al., 1998; Kaur and Ling, 1999). In the present study, 




few faintly Perls’ iron stained cells were oligodendrocytes. In the hypoxic PWM, 
though the cell body of astrocytes were not iron positive, their processes were found to 
overlap with the iron stained cells in the hypoxic PWM.  
4.3 Dysregulation of iron homeostasis in the glial cells of PWM in response to 
hypoxia 
The balance between iron uptake and release of iron from the cell is essential to 
establish the iron homeostasis (Burdo et al., 1999; Qian and Shen, 2001; Ke and Qian, 
2007) and an imbalance is implicated in most CNS diseases (Yang et al., 2011).  Based 
on this, the differential expression of proteins involved in iron metabolism (HIF-1α, 
IRP1, IRP2, TfR, DMT1, FPN1 and CP) was studied in all the three glial cells. 
4.3.1 Amoeboid Microglial Cells: 
The excess iron accumulation in AMCs could be attributed to the increase in 
TfR and DMT1 protein expression and the reduced FPN1 and CP expression. TfR and 
DMT1 could have favoured the iron uptake in hypoxic AMCs, whereas the down 
regulated expression of FPN1 and CP could have resulted in reduced export of iron 
from hypoxic AMCs leading to increased intracellular concentration of iron. 
Concomitant to this, there was an increase in iron concentration in cultured hypoxic 
microglial cells. Hence, it is suggested that the increased TfR and DMT1 expression 
might be one of the mechanisms leading to accumulation of iron in microglia following 





In the astrocytes of developing white matter, the proteins TfR, DMT, FPN1 and 
CP were up-regulated following hypoxic exposure. The changes in the expression of 
TfR, DMT1 and FPN1 in astrocytes are consistent with the findings of Yang et al. 
(2012) where the expression of proteins TfR, DMT1 and FPN1 was increased following 
hypoxic preconditioning of astrocytes. While TfR and DMT1 could have favoured in 
the uptake of iron by astrocytes, the increased expression of FPN1 and CP could have 
led to the iron efflux from the astrocytes of hypoxic PWM. This could probably explain 
the lack of iron positive astrocytes in the hypoxic PWM. Lack of iron efflux from 
astrocytes has been reported to render the neurons (Jeong and David, 2003) and 
microglia iron deficient (Schulz et al., 2012). Based on this, it could be suggested that 
the increased expression of FPN1 and CP could favour iron release into the hypoxic 
PWM which is taken up by the AMCs and oligodendrocytes. 
4.3.3 Oligodendrocytes 
Besides microglia, there were very few oligodendrocytes which were stained 
positivly for iron in the hypoxic PWM. The increase in iron in oligodendrocytes could 
have been favoured by the increased expression of TfR on the oligodendrocytes.    
The expression of proteins IRP1, IRP2 and HIF-1α was found to be 
differentially expressed in the glial cells (microglia, oligodendrocytes and astrocytes) in 
response to hypoxia. Expression of IRP1, IRP2 and HIF-1α was up-regulated in the 
AMCs and oligodendrocytes of hypoxic PWM whereas in astrocytes, only HIF-1α was 




HIF-1α, IRP1 and IRP2 regulated the expression of TfR and DMT was studied by using 
primary microglial cultures as a model system.   
4.4 Hypoxia induces expression of iron uptake proteins in microglia 
4.4.1 HIF-1α induces upregulation of TfR and DMT-1 
Hypoxic conditioning is often accompanied by the increased expression of TfR 
and DMT1, which are involved in iron uptake. Hence these proteins were identified to 
be hypoxia inducible proteins (Bianchi et al., 1999; Tacchini et al., 1999; Li et al., 
2008b; Qian et al., 2011). Consistent with this, there was a simultaneous increase in the 
expression of TfR and DMT1 along with that of HIF-1α in hypoxic microglial cultures 
and in AMC of hypoxic PWM. Treatment of hypoxic microglial cultures with KC7F2, 
an inhibitor of HIF-1α, resulted in reduced expression of TfR and DMT1 implicating a 
role for HIF-1α in mediating their expression. Owing to the presence of hypoxia 
responsive element (HRE) in the promoters of TfR and DMT1, the binding of HIF-1 to 
HRE sequence is suggested to enable their transcription (Bianchi et al., 1999; Tacchini 
et al., 1999; Qian et al., 2011). Based on the above, it is possible that there is a direct 
influence of HIF-1α over the increased iron accumulation in hypoxic microglia.  
4.4.2 Iron regulatory proteins could mediate the expression of iron uptake proteins  
Besides HIF-1α, the expression of IRPs (IRP1 and IRP2), which play a vital role 
in maintaining the cellular iron homeostasis, were found to be up-regulated in the 
hypoxic microglial cultures. The changes in the expression of IRPs in response to 
hypoxia have been previously reported (Hanson et al., 1999; Christova and Templeton, 




astrocytes has been proposed to contribute to the aberrant metabolism of iron (Kim et 
al., 2007). Though studies have previously reported that there is differential expression 
of IRPs following a hypoxic exposure in various cell lines (Toth et al., 1999; Schneider 
and Leibold, 2003; Christova and Templeton, 2007), in this study both the IRPs were 
found to be up-regulated in response to hypoxia in microglial cells. Previous reports on 
HEK293 cell line suggest the same in response to hypoxia (Schneider and Leibold, 
2003; Christova and Templeton, 2007).  The simultaneous up-regulation of TfR and 
DMT1 in hypoxic microglial cells suggests that IRPs could have favoured the enhanced 
expression of TfR and DMT1 in hypoxic microglial cells. This could be due to the post-
transcriptional regulation exerted by the IRPs by binding to the IREs in the 3’ UTR of 
mRNA of TfR and DMT1 (Thomson et al., 1999).    
Based on the above, it could be suggested that hypoxia, by means of enhancing 
HIF-1α expression, could have a direct influence over the increased iron uptake in the 
AMCs and oligodendrocytes of hypoxic PWM. In astrocytes of hypoxic PWM, while 
HIF-1α could have favoured the increased expression of TfR and DMT1, it is possible 
that HIF-1α may also result in the increased expression of FPN1 and CP. Reports stating 
that FPN1 is hypoxia inducible (Yang et al., 2012) owing to its simultaneous expression 
along with that of HIF-1α and previous demonstration showing that HIF-1, a dimer of 
HIF-1α and HIF-1β formed after the nuclear translocation of HIF-1α, is essential for   
transcriptional activation of CP (Mukhopadhyay et al., 2000); this may explain the up-
regulation of FPN1 and CP in the astrocytes in PWM following hypoxic exposure. In 
AMCs and oligodendrocytes of hypoxic PWM, the increased expression of IRP1 and 




sequence in the 5’ UTR of their mRNA (Aydemir et al., 2009). Taken together, it is 
possible that the alteration in the expression of HIF-1α, IRP1 and IRP2 in the glial cells 
could result in dysregulation of iron homeostasis in the hypoxic PWM. 
4.5 Role of iron in hypoxic microglia  
4.5.1 Iron mediated ROS production in hypoxic microglia 
Excess iron is implicated in the free radical production and in increased 
oxidative stress (Zecca et al., 2004). Iron, when present in unbound form, catalyses the 
conversion of superoxide and hydrogen peroxide to free radicals through Haber-Weiss 
and Fenton reactions (Gutteridge et al., 1982). Oxidative stress, which could lead to 
death of oligodendrocytes (Back and Rivkees, 2004), has been implicated in the 
pathogenesis of hypoxic PWMD (Haynes et al., 2003). The presence of nitrotyrosine 
and markers of lipid peroxidation suggests the free radical mediated injury in human 
PVL (Haynes et al., 2005). In the developing white matter, Welin et al. (2005) 
demonstrated the increased free radical production in response to hypoxic–ischemic 
insults and microglial cells are implicated in the free radical generation (Colton et al., 
1996). In this study, hypoxic conditioning of microglial cultures resulted in increased 
production of ROS/RNS. On treating the hypoxic microglial cultures with 
deferoxamine, the increase in ROS/RNS was abolished suggesting that increased iron 
within hypoxic microglia could have led to the increased production of free radicals. In 
addition, the diffuse release of ROS/RNS could exacerbate the PWMD by resulting in 
widespread oxidative/nitrative damage (Haynes et al., 2005).  




Activated microglia are known to secrete a plethora of cytokines which are toxic 
to oligodendrocytes (Hansson and Ronnback, 2003; Nakanishi, 2003). Activation of 
microglia by hypoxic stimulus is accompanied by overproduction of inflammatory 
cytokines such as TNF-α and IL-1β (Deng et al., 2008). Cytokines have been considered 
to play a role in the pathogenesis of PWMD (Chew et al., 2006; Folkerth, 2006).  A 
major finding in this study is the involvement of iron in inducing cytokine production 
by hypoxic microglial cells. This is supported by the decreased levels of cytokine 
production when the hypoxic microglial cells were treated with deferoxamine. This is 
further supported by the previous demonstration of increased cytokine production in 
LPS treated iron loaded microglia (Zhang et al., 2006).  In Parkinson’s disease, iron 
accumulated in substantia nigra is proposed to influence the cytokine production in 
activated microglia (Mounsey and Teismann, 2012). In human infants, who suffered 
PVL, the increased concentrations of TNF-α and IL-1β in the white matter was 
suggested to contribute to the progression of PVL (Kadhim et al., 2001). 
4.6 Role of microglial iron in inducing oligodendrocytes death 
Inflammatory mediators such as cytokines, chemokines and free radicals have 
been associated with the pathogenesis of PWMD (Chew et al., 2006; Folkerth, 2006) 
and have been proposed to mediate the death of oligodendrocytes. Here we have 
analysed some of the mechanisms by which microglial iron induced free radicals and 
cytokines effected oligodendrocyte death. 




The imbalance in the anti-oxidant and oxidant generating system in the 
developing brain predisposes the immature brain to free radical mediated damage 
(Buonocore et al., 2001; Welin et al., 2005). In response to hypoxic exposure, the 
antioxidant glutathione is reported to be reduced in PWM of neonatal rats (Kaur et al., 
2010). In addition, the intracellular glutathione content in oligodendrocytes progenitors 
account for their injury in hypoxic PWM (Back et al., 1998). Here, when 
oligodendrocytes were exposed to hypoxia or conditioned medium form hypoxic 
microglial cells, they exhibited reduced glutathione content. However, in 
oligodendrocytes treated with medium derived from deferoxamine treated hypoxic 
microglia, the glutathione levels were similar to that of control cells.  Glutathione 
depletion has been previously demonstrated to predispose the oligodendrocytes to 
damage in hypoxic-ischemic conditions (Back et al., 2002) through free radical 
mediated injury (Back et al., 1998). ROS was demonstrated to cause damage to the 
oligodendrocytes (Griot et al., 1990) by promoting lipid peroxidation (Su et al., 2011). 
In premature infants, who suffered PWMD, elevated levels of lipid peroxidation 
products such as 8-isoprostane and malondialdehyde (MDA), and protein carbonyls 
were documented in their CSF (Inder et al., 2002) suggesting their association with 
PWMD. In response to hypoxic-ischemic insult, elevated levels of malondialdehyde 
(Kaur et al., 2010) and 4-HNE (Lin et al., 2004) was demonstrated in the white matter. 
In this study, exposing the cultured oligodendrocytes to hypoxia or treating with 
conditioned medium from hypoxic microglia resulted in increased lipid peroxidation 
manifested by the high malondialdehyde levels. However, there was reduced 




deferoxamine treated hypoxic microglia.  Taken together these results suggest that the 
iron induced ROS/RNS release by hypoxic microglia could have resulted in reduced 
glutathione content and increased lipid peroxidation.  
4.6.2 IL-1β reduced oligodendrocyte proliferation 
IL-1β is nontoxic to the oligodendrocytes, yet it was demonstrated to inhibit the 
proliferation of oligodendrocytes (Vela et al., 2002) by inhibiting growth factor induced 
activation of p42/p44 MAPK pathway (Vela et al., 2002). Evidence for IL-1β induced 
inhibition of oligodendrocyte proliferation was derived from the proliferation assay. 
When oligodendrocytes were treated with conditioned medium from hypoxic microglia, 
there was an increase in inhibition of proliferation. On the contrary, when the cells were 
treated with medium derived from hypoxic microglia treated with deferoxamine or 
medium neutralized with IL-1β antiserum, there was negligible inhibition of 
proliferation.  In hypoxic PWM, significant increase in IL-1β production by microglial 
cells and simultaneous expression of IL-1 receptor I on oligodendrocytes has been 
demonstrated (Deng et al., 2008). These results imply that the increased concentrations 
of IL-1β in the hypoxic PWM could delay the proliferation of oligodendrocytes and 
thereby the recovery of PWMD.  
4.6.3 TNF-α induced caspase-3 labelling 
TNF-α is implicated in inducing apoptosis of oligodendrocytes (Ladiwala et al., 
1999; Buntinx et al., 2004). As death of oligodendrocytes is a hallmark feature of 
PWMD (Back et al., 2002) and enhanced levels of TNF-α is present in hypoxic PWM 




Mechanistic studies on TNF-α induced apoptosis in septo-hippocampal neuronal 
cultures demonstrated that treatment with TNF-α resulted in activation of caspase-3 
(Zhao et al., 2001). Further, in oligodendrocytes treated with TNF-α, apoptosis was 
reported to be mediated by JNK-p53 pathway (Ladiwala et al., 1999) and was caspase 
dependent (Wosik et al., 2003). Caspase-3 is known to be activated only during 
apoptosis (Armstrong et al., 1996; Wang et al., 1996) and from our present results it 
could be suggested that TNF-α induced apoptosis of oligodendrocytes, as there was 
increased caspase-3 labelling in oligodendrocytes treated with conditioned medium 
from hypoxic microglia. On the contrary, there was reduced caspase-3 labelling in 
oligodendrocyte cultures when subjected to treatment with medium derived from 
hypoxic microglia treated with deferoxamine or neutralized for TNF-α and this could be 
attributed to the reduced TNF-α levels in the conditioned medium. The damaging role 
of TNF-α is further supported by the demonstration of increased expression of TNF 
receptor I in the oligodendrocytes of hypoxic PWM (Deng et al., 2008). Taken together 
these results indicate that iron accumulation in microglia indirectly result in damage of 
oligodendrocytes by enhancing the secretion of free radicals and cytokines from 
hypoxic microglia which are implicated in the pathogenesis of PWMD.  
4.6.4 Factors released by iron accumulated hypoxic microglia mediated 
oligodendrocyte apoptosis 
Besides the above, the damaging role of iron accumulation within hypoxic 
microglia is further supported with the demonstration of apoptosis of oligodendrocytes 
derived from the TUNEL assay.  The toxicity of the conditioned medium derived from 




oligodendrocytes. This could be attributed to the cytotoxic molecules, such as ROS and 
cytokines secreted by iron accumulated hypoxic microglia. Additional support for the 
microglial iron mediated apoptosis of oligodendrocytes comes from the demonstration 
of reduced TUNEL labelling in oligodendrocytes treated with conditioned medium 
derived from deferoxamine treated hypoxic microglia in comparison to those treated 
with medium from hypoxic microglia not treated with deferoxamine. Therefore, iron 
accumulation within hypoxic microglia, by enhancing the secretion of factors such as 
ROS, TNF-α and IL-1β, could indirectly result in death of oligodendrocytes. 
4.7 Iron may disrupt BBB by facilitating MMP-9 production in AMCs 
Activated microglia have been previously demonstrated to synthesise MMPs 
which are a family of extracellular matrix degrading enzymes. Gottschall et al. (1995) 
have demonstrated the production of MMP-9 in microglia challenged with LPS. In this 
study, hypoxia was found to up-regulate the expression of MMP-9 in the AMCs. This 
increase could have been favoured by the iron accumulated in microglia, as 
deferoxamine treatment led to decreased MMP-9 production by AMCs. Iron induced 
MMP-9 production in microglial cultures was demonstrated recently when challenged 
with LPS (Mairuae et al., 2011). MMP-9 has been reported to cause BBB disruption by 
degrading the basal lamina (Rosenberg and Yang, 2007). In animal models, in response 
to intracerebral injection of TNF-α, there was increased secretion of MMP-9 which was 
associated with BBB damage (Rosenberg et al., 1995).  Hence, it could be speculated 
that the MMP-9 produced by iron accumulated microglia in hypoxic PWM could result 




4.8 Mechanism involved in deferoxamine mediated anti-inflammatory activity 
4.8.1 Deferoxamine involves MAPK pathway 
Deferoxamine has been demonstrated to suppress microglial activation (Wu et 
al., 2011; Miao et al., 2012) and the results from the present study also suggest the 
same. The mechanism by which deferoxamine induced a reduction in free radicals and 
cytokine production in hypoxic microglia is yet to be elucidated. Microglia actively 
responds to a wide range of noxious stimuli and the intracellular MAPK signalling 
pathway activated in response to these signals has been reported to mediate cell survival 
and inflammatory pathway in microglia (Huo et al., 2011; Qu et al., 2012).  In hypoxic 
microglial cultures, enhanced production of cytokines is effected via the MAPK 
signalling pathway (Deng et al., 2008) and previous studies have reported the 
interaction between iron and MAPK signalling pathway (Huang et al., 2007; Mardini et 
al., 2010). Based on the above, in the present study, the expression of MAPKs in 
response to iron accumulation in microglia was analysed. Among the three MAPKs, 
ERK and P38 responded differentially with respect to changes in iron level within 
microglia, whereas, the changes exhibited by JNK were not significant. Hypoxic 
conditioning of microglia resulted in activation of ERK and P38 through 
phosphorylation, whereas, chelation of iron from hypoxic microglia with deferoxamine 
or treatment with KC7F2 resulted in up-regulation of p-ERK and reduction in p-P38. 
This is in accordance with a previous study which showed the same changes in MAP 
kinases in epidermal JB6 cells subjected to iron overload and then treated with 
deferoxamine (Huang et al., 2007).  




Activation of ERK is often reported to induce genes responsible for proliferation 
and differentiation, via subsequent activation of transcription factors (Boulton et al., 
1991; Marshall, 1995; Segal and Greenberg, 1996) such as CREB and AP1 (Huang et 
al., 2007).  Though studies have previously demonstrated the repression of p-ERK in 
activated microglia, in association with anti-inflammatory effect of various drugs, our 
results show an enhanced expression of p-ERK in hypoxic microglia treated with 
KC7F2 or deferoxamine. Very few studies have demonstrated enhanced expression of 
p-ERK in microglia in response to drugs such as dibutyryl cAMP and docosahexaenoic 
acid (Woo et al., 2003; Lu et al., 2010). Up-regulation of p-ERK has been reported to be 
an anti-inflammatory signal in endothelial cells (Maeng et al., 2006). In microglia 
challenged with interferon-γ and treated with docosahexaenoic acid, increased p-ERK 
was linked with the reduced microglial oxidative and pro-inflammatory response (Lu et 
al., 2010).  Furthermore, our results suggest that the up-regulated p-ERK in hypoxic 
microglia treated with deferoxamine or KC7F2 resulted in activation of its downstream 
target CREB. CREB activation in microglia has been demonstrated to induce production 
of growth factors such as IGF-1 in animal models of status epilepticus (Choi et al., 
2008). In addition, p-CREB is reported to induce MAPK de-activating dual specificity 
phosphatases, MKP-1 (Casals-Casas et al., 2009). CREB mediated MKP-1 up-
regulation in response to MAPK signalling has been reported by many studies 
(Sgambato et al., 1998; Lu et al., 2008). MKP-1 inhibits MAPK pathway by 
dephosphorylating the MAP kinases through a negative feedback loop mechanism 
(Chen et al., 2002; Lasa et al., 2002; Zhou et al., 2007). The induction of MKP-1 in 




oxidative damage (Zhou et al., 2006). In this study, the simultaneous up-regulation of 
MKP-1 along with that of p-CREB in deferoxamine treated microglial cells suggests 
that p-ERK mediated p-CREB might have induced the production of MKP-1.   
4.8.3 Deferoxamine inactivates p-P38 via p-ERK-CREB-MKP-1 pathway 
Contrary to deferoxamine/KC7F2 induced p-ERK upregulation, the expression 
of p-P38 was found to be decreased in hypoxic microglial cells treated with 
deferoxamine/KC7F2. P38 activated by various stress stimuli including hypoxia, 
mediates the production of inflammatory cytokines in microglia (Lee et al., 2000; 
Koistinaho and Koistinaho, 2002; Deng et al., 2008). Addition of P38 inhibitor 
SB202190 to hypoxic microglia has been previously reported to reduce TNF-α and IL-
1β levels in activated microglia (Lokensgard et al., 2001) and the same was observed in 
the present study. As stated above, iron mediates the production of pro-inflammatory 
cytokines TNF-α and IL-1β in activated microglia (Zhang et al., 2006) and from the 
finding that deferoxamine reduced p-P38, it could be explained that iron induced 
cytokine production in hypoxic microglia might be mediated through activation of P38. 
However, the pathway through which deferoxamine could result in inactivation of P38 
has remained unexplained. A possible explanation for this could be the enhanced 
expression of MKP-1 in hypoxic microglia treated with deferoxamine. MKP-1 induced 
dephosphorylation of P38 in microglia has been reported by many studies and this was 






4.9 Iron accumulation in hypoxic cultured oligodendrocytes   
There was increased iron accumulation in cultured oligodendrocytes in response 
to hypoxic conditioning and the concentration of iron accumulated was ten times lower 
than that of microglial iron concentrations. Pertubations in the iron levels were 
suggested to result in the injury of oligodendrocytes (Griot et al., 1990; Connor and 
Menzies, 1996). Further support to this comes from the study of Kress et al. (2002), 
wherein the increased intracellular concentration of iron was demonstrated to be toxic to 
the oligodendrocytes.   
4.10 Endoplasmic stress in response to iron accumulation in hypoxic 
oligodendrocytes 
In response to hypoxia, the ER in the oligodendrocytes was dilated or ballooned 
whereas the structure of ER was preserved in control cells. This nature of dilated ER has 
been demonstrated in lung epithelial fibroblast in response to capsaicin treatment (Oh 
and Lim, 2009).  Hypoxia is known to result in protein mis-folding which induces ER 
stress response (Rao and Bredesen, 2004; Xu et al., 2005), yet, the underlying 
mechanism has not been elucidated. Hypoxia induced production of NO or free radicals 
were reported to lead to protein misfolding by depleting Ca2+ stores in the ER through 
RyR (Xu et al., 2005). Hypoxic conditioning of primary oligodendrocytes resulted in 
the up-regulation of RyR which could evoke the ER stress response in hypoxic 
oligodendrocytes. The interesting finding is that the increased expression of RyRs is 
mediated by the increased iron accumulation, as treating the oligodendrocytes with 
deferoxamine resulted in down regulation of RyR expression. The support for this could 




cells (Munoz et al., 2006). Additional support comes from the present study, were in the 
dilatation of ER observed in hypoxic oligodendrocytes was diminished in hypoxic 
oligodendrocytes treated with deferoxamine suggesting ER stress attenuation.  
Endoplamic stress was evident in the hypoxic oligodendrocytes with the up-regulation 
of IRE-1α, Bip and downregulation of PERK.  IRE-1α is known to play a central role in 
the unfolded protein response in the ER (Oikawa et al., 2009). Increase in IRE-1α is 
associated with the pathogenesis of several diseases including ischemic brain injury (Ito 
et al., 2001; Nakayama et al., 2010). In addition, IRE-1α is known to mediate the 
synthesis of Bip (Ito et al., 2001). Bip is known to be induced when there is 
accumulation of misfolded proteins in the ER (Gething, 1999) and is known to aid in 
the folding of proteins at the expense of ATP hydrolysis (Blond-Elguindi et al., 1993). 
IRE-1α mediated increase in Bip has been suggested to mediate cell death (Ito et al., 
2001). PERK is essential for translational attenuation in the ER (Harding et al., 2000). 
The downregulation of PERK in the hypoxic oligodendrocytes suggest an impairment in 
the translational repression mechanism in ER leading to continuous production of 
unfolded protein. Sustained ER stress has been reported to result in apoptosis of cells 
(Tsang et al., 2010). This is confirmed by the up-regulation of p53 in the hypoxic 
oligodendrocytes. Up-regulated p53 could lead to cleavage of caspase-3 and could result 
in death of oligodendrocytes. This could be supported by the simultaneous up-regulation 
of caspase-3 in hypoxic oligodendrocytes. However, the ER changes found in hypoxic 
oligodendrocytes were reversed when treated with deferoxamine suggesting that iron 




stated that iron accumulation within hypoxic oligodendrocytes could directly cause their 
death by evoking ER stress. 























From the results of the present study it is confirmed that hypoxic exposure 
results in iron accumulation in the PWM of immature brains. Along with this the 
disruption of iron homeostasis was evident from the increased expression of HIF-1α, 
IRP1, IRP2, TfR, DMT1, FPN1 and CP. These results suggest that a dysregulation in 
iron metabolism could favour iron accumulation in hypoxic PWM. In association with 
this, the major finding was the localisation of iron in AMCs of the hypoxic PWM. 
 The iron accumulation was favoured by the simultaneous expression of HIF-1α, 
IRP1 and IRP2, which enhanced the expression of TfR and DMT1 in hypoxic 
microglia.  The present results have shown that besides the post-transcriptional control 
exhibited by IRPs, there exists a transcriptional control by HIF-1α on the proteins 
involved in iron uptake. Hence, it might be possible that the expression of TfR and 
DMT1 may be solely influenced by hypoxia. The role of excess iron within hypoxic 
microglia elucidated with the help of the iron chelator deferoxamine suggested that iron 
in hypoxic microglia mediated the increased production of ROS, TNF-α and IL-1β that 
cause apoptosis of oligodendrocytes. This is further supported by the demonstration of 
reduced cytokine levels in hypoxic animals injected with deferoxamine.  
 Besides the above, the increased iron in hypoxic PWM could result in 
exacerbation of PWMD by disrupting the BBB. AMCs in response to hypoxia resulted 
in increased production of MMP-9 which is known to disrupt the BBB. Administration 
of deferoxamine to hypoxic animals decreased the expression of MMP-9 in AMCs of 
hypoxic PWM. Hence, these results implicate increased accumulation of iron in 




Associated with the enhanced ROS and cytokine levels in hypoxic microglia 
was the increased apoptosis of oligodendrocytes when treated with conditioned medium 
from hypoxic microglia. The role of iron in causing apoptosis was attributed to the 
mechanisms that it exerts on oligodendrocytes such as reduction of their glutathione 
levels, increased malondialdehyde levels, increased caspase-3 expression, and decreased 
proliferation. This was, however, reversed when oligodendrocytes were subjected to 
treatment with conditioned medium from hypoxic microglia with added deferoxamine. 
Supporting the protection rendered by deferoxamine is the reduced apoptosis of 
oligodendrocytes. 
The protective role of deferoxamine in inhibiting iron induced pro-inflammatory 
cytokines secretion by hypoxic microglia was possible by inhibiting the 
phosphorylation of P38. Treatment with deferoxamine induced p-ERK mediated up-
regulation of p-CREB in hypoxic microglia. This increase in p-CREB might have led to 
the enhanced production of MKP-1, which is known to deactivate the MAP kinases by 
dephosphorylating them. Although KC7F2 resulted in increased MKP1 when compared 
to hypoxic microglia, the increase was not significant suggesting an incidental role of 
KC7F2 in rendering protection against iron induced PWMD. Taken together, it could be 
inferred that deferoxamine may alleviate the PWMD by reducing p-P38 mediated 
cytokine production and is favoured by the enhanced MKP-1 production in microglia 




Primary oligodendrocytes subjected to hypoxia were found to accumulate 
iron and the ability of increased iron in causing their death was also considered. The 
increased iron within oligodendrocytes induced ER stress by evoking RyR response. In 
association with this, an up-regulation of Bip and IRE-1α was demonstrated implying 




alternative mechanism to alleviate ER stress was dysfunctional in the hypoxic 
oligodendrocytes leading to increased misfolded proteins. However, treatment with 
deferoxamine reversed the expression levels of Bip, IRE-1α and PERK to control levels 
Fig V An illustration demonstrating the cellular and molecular events associated 
with iron accumulation in glial cells in response to hypoxic insult and the role of iron 




in hypoxic oligodendrocytes. Associated with this, there was reduced p53 levels in 
hypoxic oligodendrocytes treated with deferoxamine indicating a reduced apoptosis. 
Taken together, it could be suggested that the increased iron accumulation in the 
hypoxic PWM may increase the incidence of apoptotic oligodendrocytes either 
indirectly by enhancing the secretion of cytotoxic factors from hypoxic microglia or 
directly by inducing ER stress in the highly vulnerable oligodendrocytes. 
The overall data has presented the cellular and molecular events (Fig V) that 
could result in iron induced damage of hypoxic PWM. In conclusion, a clearer 
understanding of the iron homeostasis ensured by the glial cells and the mechanisms by 
which this is impaired could be of use in developing alternative therapeutic strategies in 
















Clinical Significance and scope for future study 
 
Currently, there is no treatment for PWMD and the available therapies target the 
secondary pathologies which develop as a result of PWMD. Though several 
medications have been proposed to alleviate PWMD in infants none of them have been 
approved so far for use owing to the complications and limitations involved. Based on 
the present study, it could be suggested that drugs such as deferoxamine targeting iron 
induced damage, may have potential in ameliorating hypoxia-induced PWMD in the 
neonates.  
The iron chelator, deferoxamine is in clinical use for many years for treating acute and 
chronic iron overload. In addition, deferoxamine is prescribed for patients with 
aceruloplasmia (Miyajima et al., 1997). However, its neuroprotective nature is yet to be 
demonstrated owing to the limited data available. In cardiac patients, during coronary 
artery bypass grafting, intravenous injection of deferoxamine was proved beneficial as it 
protected the myocardium from reperfusion injury (Paraskevaidis et al., 2005). In 
addition, the neuroprotective effect of deferoxamine was suggested by a pilot study 
involving 7 patients with stroke. The protective role of deferoxamine in this was 
attributed to the reduced lipid peroxidation product and increased total radical trapping 
antioxidant capacity in the serum (Selim, 2009; Selim et al., 2011). The efficiency of 
deferoxamine needs to be investigated in the neonates suffering from PVL/PWMD. 
Furthermore, in this study, the alterations in the regulation of iron homeostasis have 
been suggested to be the major cause for iron accumulation in the brain. Future studies 




the complex iron accumulation pathway and in newer therapeutic alternatives which are 
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Fig 1. Light microscopic image  of coronal section of 4d old rat brain in A showing the 
region of interest, the PWM (specifically the corpus callosum demarcated by dotted 
line) located above the lateral ventricles (V). Confocal images in panels B-E shows the  
blood vessels and glial cells in the PWM- B-Blood vessels (*) and AMCs (arrows) 
marked by lectin, C- AMCs marked by OX42, D- astrocytes marked by GFAP and E- 















Fig 2. Bar graph shows the concentration of iron in the PWM of postnatal rats sacrificed 
at 3 and 24 h, 3, 7, and 14 d after hypoxic exposure along with their corresponding 
controls. The iron content at each time points is represented as meanേSD. Significant 















Fig 3. The protein expression of IRP1, IRP2, and HIF-1α in the hypoxic PWM isolated 
at 3 and 24 h, 3, 7, and 14 d following hypoxic exposure and their corresponding 
controls.  A: shows the immunoreactive bands for IRP1 (97 kDa), IRP2 (105 kDa), HIF-
1α (110 kDa)  and β actin (43 kDa). B-D are their corresponding bar graphs showing the 
changes in the optical density between control and hypoxic group, shown as mean.േ 
SD. Significant differences in protein levels between hypoxic and control groups are 
indicated as *(p<0.05) and **(p<0.01). 
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170 
Fig 4. Western blotting of TfR, DMT1, FPN1 and CP in the PWM of postantal rats at 3 
and 24 h, 3, 7, and 14 d following hypoxic exposure and their corresponding controls. 
Panel A shows the immunoreactive bands for TfR (95 kDa), DMT1 (68 kDa), FPN1 (63 
kDa), CP (130 kDa)  and β actin (43 kDa). B-E are their corresponding bar graphs 
showing the significant  changes in the optical density between control and hypoxic 
group (plotted as meanേSD). Significant differences in protein levels between hypoxic 
and control groups are expressed as follows: *(p<0.05) and **(p<0.01). 
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Fig 5. Confocal images showing the localisation of TfR (Aa-f) and DMT1 (Ba-f) to the 
blood vessels (*) and in AMCs (arrows) in the PWM of rats killed at 3d after hypoxic 
exposure along with its age matched control. Expression of lectin (A, Ba,d: green), TfR 
(Ab,e: red), DMT1 (Bb,e: red), and a colocalization of lectin with TfR and DMT1 (A–
Bc,f ). Scale bars: A–B, 20μm.
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Fig 6. Confocal images showing the cellular localisation of FPN1 (Aa-f) and CP (Ba-f) 
to the blood vessels (*) and in AMCs (arrows) in the PWM of rats killed at 3d after 
hypoxic exposure along with its age matched control. Expression of lectin (A, Ba,d: 
green), FPN1 (Ab,e: red), CP (Bb,e: red), and a colocalization of lectin with FPN1 and 
CP (A–Bc,f ). Scale bars: A–B, 20μm.  
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Fig 7. A: Light-microscopic image of a coronal section of brain stained with Perls’ iron 
solution and counter stained with methyl green showing iron positive cells (brown) in 
the PWM. B Confocal images of Perls’ iron-stained sections showing the localisation of 
iron in lectin positive microglial cells in the PWM at 3 d after hypoxic exposure and 
their corresponding controls. Distribution of lectin (Ba,d; green) and iron (Bb,e; black) 
is localized in AMCs (arrows) in the PWM in overlays Bc, and Bf (merge). Note the 
significant increase in iron positive microglial cells in hypoxic PWM. Scale bars- 50μm.
177 
Figures and Figure legends 
178 
Fig 8. Panel A, B shows the distribution of Perls’ iron positive cells in sections of PWM 
which were immunolabelled for astrocytes (marked by GFAP) and oligodendrocytes 
(marked by CC1) at 3 d following hypoxic exposure and in their corresponding controls. 
Distribution of GFAP (Aa,d; red), CC1 (Ba,d: red) and iron (A,Bb,e; black) and their 
Merge (A,B c,f)). Note that the cells bodies of astrocytes  does not overlap with iron 
positive cells . Oligodendrocytes colocalize with faintly iron stained cells in response to 
hypoxia.   Scale bars- 50μm.  
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Fig 9. Confocal images showing the expression of HIF-1α (Aa-f), IRP1 (Ba-f) and IRP2 
(Ca-f) in the AMCs marked by OX42 in the PWM at 3d after hypoxic exposure. 
Distribution of OX42 (A,b,C a,d: green), HIF-1α (Ab,e: red), IRP1 (Bb,e: red), IRP2 
(Cb,e: red) and a colocalization of OX42 with HIF-1α, IRP1 and IRP2 (A–Cc,f ). Note 
the significant increase in HIF-1α, IRP1 and IRP2 in AMCs following hypoxic 
exposure. Scale bars: A–B, 20μm. 
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Fig 10. Confocal images showing the expression of TfR (Aa-f) and DMT1 (Ba-f) to the 
AMCs marked by OX42 in the PWM at 3d after hypoxic exposure. Distribution of 
OX42 (Aa,d: red; Ba,d: green), TfR (Ab,e: green), DMT1 (Bb,e: red), and a 
colocalization of OX42 with TfR and DMT1 (A–Bc,f ). Note the significant increase in 
TfR and DMT1 in microglia following hypoxic exposure. Scale bars: A–B, 20μm.
183 
Figure and Figure legends 
184 
Fig 11. Co-localization of FPN1 (Aa-f) and CP (Ba-f) to the AMCs (marked by OX42) 
in the PWM of rats at 3d following hypoxia along with its control. Expression of OX42 
(A, Ba,d: green), FPN1 (Ab,e: red), CP (Bb,e: red), and a colocalization of OX42 with 
FPN1 and CP (A–Bc,f ). Note the presence of FPN1 positive cell (Ae,f: arrow head) 
which is not identified to be AMC. Scale bars: A–B, 20μm.  
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Fig 12.  Confocal images showing the expression of HIF-1α (Aa-f), IRP1 (Ba-f) and 
IRP2 (Ca-f) in GFAP labelled astrocytes in the PWM of rats at 3d after hypoxic 
exposure. Distribution of GFAP (A,B,Ca,d: red), HIF-1α (Ab,e: green), IRP1 (Bb,e: 
green), IRP2 (Cb,e: green) and a colocalization of GFAP with HIF-1α, IRP1 and IRP2 
(A–Cc,f ). Note the significant increase in HIF-1α, in astrocytes following hypoxia. 
Scale bars: A–C, 20μm. 
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Fig 13. Confocal images in panel A,B shows the co-localisation of TfR (Aa-f) and 
DMT1 (Ba-f) to the astrocytes (marked by GFAP) in the PWM of rats killed at 3d after 
hypoxic exposure along with its control. Expression of GFAP (Aa,d : red, Ba,d: green), 
TfR (Ab,e: green), DMT1 (Bb,e: red), and a colocalization of GFAP with TfR and 
DMT1 (A–Bc,f ). Note the upregulation of TfR and DMT1 in the astrocytes following 
hypoxic exposure. Note the presence of TfR positive cells (Ae,f: arrow heads) which are 
not identified to be astrocytes. Scale bars: A–B, 20μm.  
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Fig 14. Panel A,B shows the co-localisation of FPN1 (Aa-f) and CP (Ba-f) to the 
astrocytes (marked by GFAP) in the PWM of rats killed at 3d after hypoxic exposure 
along with its control. Expression of GFAP (A, Ba,d: green), FPN1 (Ab,e: red), CP 
(Bb,e: red), and a colocalization of GFAP with FPN1 and CP (A–Bc,f ). Note the 
increase in expression of FPN1 and CP in astrocytes following hypoxia. Scale bars: A–
B, 20μm.  
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Fig 15.  Confocal images showing the expression of HIF-1α (Aa-f), IRP1 (Ba-f) and 
IRP2 (Ca-f) in CC1 labelled oligodendrocytes in the PWM of rats at 3d after hypoxic 
exposure. Distribution of CC1 (A,B,Ca,d: red), HIF-1α (Ab,e: green), IRP1 (Bb,e: 
green), IRP2 (Cb,e: green) and a colocalization of CC1 with HIF-1α, IRP1 and IRP2 
(A–Cc,f ). Note the significant increase in HIF-1α, IRP1 and IRP2 in oligodendrocytes 
following hypoxia. Note the presence of cells which are positive for HIF-1α (Ae,f: 
arrow heads)  but not marked by CC1. Scale bars: A–C, 50μm. 
193 
Figure and Figure legends 
194 
Fig 16.  Confocal images showing the expression of TfR (Aa-f) and DMT1 (Ba-f) in 
CC1 labelled oligodendrocytes in the PWM of rats at 3d after hypoxic exposure. 
Distribution of CC1 (A,Ba,d: red), TfR (Ab,e: green), DMT1 (Bb,e: green), and a 
colocalization of CC1 with TfR and DMT1 (A–Bc,f ). Note the significant increase in 
TfR in oligodendrocytes following hypoxia. Note the expression of TfR in blood vessel 
(Ae,f: *) and in few cells (Ae,f: arrow heads) that are not identified to be 
oligodendrocytes.  Scale bars: A–B, 20μm. 
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Fig 17. Confocal images showing the co-localisation of FPN1 (Aa-f) and CP (Ba-f) to 
the CC1 labelled oligodendrocytes in the PWM of rats at 3d follwoing hypoxia along 
with its control. Expression of CC1 (A, Ba,d: green), FPN1 (Ab,e: red), CP (Bb,e: red), 
and a colocalization of CC1 with FPN1 and CP (A–Bc,f ). Scale bars: A–B, 20μm. 
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Fig 18.  Bar graph shows the significant changes in the total iron content in control (C), 
hypoxic (H) and deferoxamine treated hypoxic microglial (H+D) culture. Note the 
significant increase in iron levels in hypoxic microglia (H) and the subsequent decrease 
in iron levels in hypoxic microglial cells when treated with deferoxamine (H + 
D).Significant differences between control (C), hypoxic (H), and deferoxamine treated 
groups are expressed as follows: * (p<0.05) and ** (p<0.01).  
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Fig 19 A: Confocal images showing control , hypoxic and deferoxamine treated hypoxic 
microglial (Hyp + Def) cultures stained with Perls’ iron-solution. Distribution of lectin 
(Aa, d, g: green) and iron localization (Ab, e, h: black) is seen in microglia (arrows) 
(Ac, f, i). Scale bars -50μm.  Bar graph in B shows the significant differences in  the 
percentage of  Perls’ positive microglia. Significant differences between the groups are 
expressed as follows: * (p < 0.05) and ** (p < 0.01). 
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Fig 20. Confocal images showing localization of HIF-1α (Aa-f), IRP1 (Ba-f) and IRP2 
(Ca-f) to the microglial cultures (marked by OX42) following a hypoxic exposure of 4 
hours. Expression of OX42 (A, B, Ca,d: green), HIF-1α (Ab,e: red), IRP1 (Bb,e: red), 
IRP2 (Cb,e: red)  and their colocalization with OX42 (A, B, Cc,f). Scale bar: A- 50μm, 
B,C- 20μm. 
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Fig 21. Western blot showing the expression of HIF-1α, TfR and DMT1 in the primary 
microglial culture exposed to hypoxia for different durations from 2h to 6h. Panel A 
shows the immunoreactive bands of HIF-1α (110 kDa), TfR (95kDa) and DMT1 
(68kDa). B-D are their corresponding bar graphs showing significant changes in the 
optical density between control and hypoxic groups (given as mean ± SD). Significant 
differences in protein levels between hypoxic and control groups are expressed as 
follows: * (p < 0.05) and ** (p < 0.01).  
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Fig 22. Western blotting showing the changes in protein levels in TfR and DMT1 when 
the microglial cultures were treated with KC7F2. A shows the immunoreactive bands 
for TfR (95kDa) and DMT1 (68kDa). B,E are their corresponding bar graphs showing 
significant differences in all four groups (control (C), control with KC7F2 (a HIF-1α 
inhibitor) (C+K), hypoxia (H) and Hypoxia + KC7F2 (H+K)). Note the significant 
reduction in TfR and DMT1 levels in KC7F2 treated hypoxic microglia in comparison 
to that of hypoxic microglia. Significant changes are represented as *(p<0.05) with 
respect to control and # (p< 0.05) with respect to hypoxia. 
 207 
 
Figure and Figure legends 
208 
Fig 23. Western blot showing the protein expression of IRP1 and IRP2 in the primary 
microglial culture. B-C are their corresponding bar graphs showing significant changes 
in the optical density between control (C) and hypoxia (H) (given as meanേSD). 
Significant differences in protein levels between hypoxic and control groups are 
expressed as follows: *p < 0.05. 
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Figure 24. Bar graph in A represents the intracellular ROS estimated in primary 
microglial cells using 10μM CM-H2DCFDA. Note the increase in ROS levels in 
hypoxic microglial cells when compared to control cultures (C). The increase in ROS 
was abolished when treated with deferoxamine. Bar graph in B represents the total 
ROS/RNS released by control (C), hypoxia (H), and hypoxia +deferoxamine (H+D) 
microglia into the conditioned medium at the end of 4h of treatment.
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Fig 25: Confocal images showing the colocalization of OX42 (Aa, d, g:green) and TNF-
α (Ab, e, h: red) in control (C), hypoxia (H), and hypoxia+deferoxamine (HD) 
microglia. Note enhanced TNF- immunofluorescence is attenuated with deferoxamine 
treatment. Scale bars-20µm The bar graph in B shows the concentration of TNF-α 
released into the medium by control (C), hypoxia (H), and hypoxia+deferoxamine (HD) 
microglia.
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Fig 26: Confocal images showing the colocalization of OX42 (Aa, d, g:green) and IL-1β 
(Ab, e, h: red) in control (C), hypoxia (H), and hypoxia+deferoxamine (HD) microglia. 
Note enhanced IL-1β immunofluorescence is attenuated with deferoxamine treatment. 
Scale bars-20µm. The bar graph in B shows the concentration of IL-1β released into the 
medium by control (C), hypoxia (H), and hypoxia+deferoxamine (HD) microglia. 
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Fig 27 Bar graph in A shows the changes in glutathione content in primary 
oligodendrocytes in control group (C), oligodendrocytes treated with conditioned 
medium from control microglia (CCM), oligodendrocytes treated with deferoxamine 
(DCM), hypoxic oligodendrocytes (H), oligodendrocytes treated with conditioned 
medium from hypoxic microglia (HCM), and with conditioned medium from 
deferoxamine treated hypoxic microglial cells (DHCM). Bar graph in B represents  the 
changes in malonaldehyde concentrations in oligodendrocyte cultures in all six groups. 
Significant differences between the groups are expressed as follows: *(p<0.05), 
**(p<0.01) with respect to control; and #(p<0.05), ##(p<0.01) with respect to hypoxia.
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Fig 28. The bar graph represents the change in  proliferation of oligodendrocytes in 
control group (C), oligodendrocytes treated with conditioned medium from control 
microglia (CCM), oligodendrocytes treated with deferoxamine (DCM), 
oligodendrocytes treated with IL-1β + anti-IL-1β (treated with 100 pg/ml IL-1β peptide 
neutralized with 10µg/ml anti-IL-1β), oligodendrocytes treated with conditioned 
medium from hypoxic microglia (HCM), and with conditioned medium from 
deferoxamine treated hypoxic microglial cells (DHCM), and HCM+anti-IL-1β (treated 
with conditioned medium from hypoxic microglia containing 10µg/ml anti-IL-1β). Note 
the increase in inhibition of proliferation in oligodendrocytes treated with HCM. 
Significant differences between the various groups are expressed as follows: *(p < 
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Fig 29. Confocal images showing caspase-3 (Cas-3)-labelling in  oligodendrocytes  in 
response to treatment with TNF-α [Aa, CC1 (green);  Ab, Cas-3 (red); Ac, CC1+Cas-
3+DAPI (blue)]. B-D, Caspase-3 labelling of oligodendrocytes in control group (C), 
oligodendrocytes treated with conditioned medium from control microglia (CCM), 
oligodendrocytes treated with deferoxamine (DCM), oligodendrocytes treated with 
conditioned medium from hypoxic microglia (HCM), with conditioned medium from 
deferoxamine treated hypoxic microglial cells (DHCM) and with medium from hypoxic 
microglia neutralized with anti-TNF-α (10μg/ml). C  shows the confocal images of cells 
that are caspase-3 positive in all groups, D shows the colocalization of CC1, caspase-3, 
and DAPI-positive cells (green, CC1; red, Cas-3; blue, DAPI). Scale bars - 50μm. The 
bar graph in E shows the significant difference in percentage of caspase-3-positive cells 
in all groups including HCM +anti-TNF-α. 
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Fig 30. TUNEL assay of oligodendrocytes showing a significant increase in apoptosis 
following hypoxia and on treatment with conditioned medium from microglial cells 
subjected to hypoxia. A shows the confocal images of DAPI-stained nucleus in all of 
the groups, B shows the confocal images of cells that are TUNEL positive in all of the 
groups, and C shows the co-localization of DAPI- and TUNEL-positive cells. Bar graph 
in D shows the percentage of cells that are TUNEL positive in each group (C, control; 
CCM, treated with conditioned medium control microglia; DCM, treated with 
deferoxamine; H, hypoxia; HCM, treated with conditioned medium from hypoxic 
microglia; DHCM, treated with conditioned medium from hypoxic microglial cells plus 
deferoxamine). Scale bars-50µm. Significant differences between the various groups are 
expressed as follows: *(p<0.05), **(p<0.01) with respect to control; and #(p<0.05), 
##(p<0.01) with respect to hypoxia.  
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Fig 31: Confocal images showing the colocalization of OX42 (a, d, g:green) and MMP-
9 (b, e, h: red) in control, hypoxic, and deferoxamine (Hyp+Def) treated hypoxic PWM. 
Note the enhanced MMP-9 immunofluorescence in hypoxic AMCs was attenuated with 
deferoxamine treatment. Scale bars a-i - 20µm.  
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Fig 32. Western blotting showing significant differences in proteins levels of MAP 
kinases (p-ERK, p-P38 and p-JNK) in various group of microglial cultures (control (C), 
control with KC7F2 (C+K), control with deferoxamine (C+D), hypoxia (H), Hypoxia + 
KC7F2 (H+K) and hypoxia + deferoxamine (H+D)). A shows the immunoreactive 
bands for p-ERK (42/44 kDa), p-P38 (43 kDa) and JNK (46/54 kDa). B,C,D  shows 
their respective bar graphs. Note the significant changes in protein levels for p-ERK and 
p-P38. The significant changes were represented as *P < 0.05, **P <0.01 with respect to 
control microglial group and #p<0.05, ##p<0.01 with respect to hypoxic microglia.
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Fig 33 Confocal images showing the co-localization of OX42 (A a, d, g: green), p-ERK 
(Ab, e, h: red)  in control, hypoxia, and hypoxia + deferoxamine microglia. Note the 
significant increase in p-ERK in hypoxic microglia treated with deferoxamine in 
comparison to the hypoxic microglia. Scale bars a-i - 50μm.  
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Fig 34 Confocal images showing the difference in expression of P38 in control, 
hypoxia, and hypoxia + deferoxamine microglia.  Expression of  OX42 (a, d, g: green), 
p-P38 (b, e, h: red)  is shown in control, hypoxia, and hypoxia + deferoxamine 
microglia. Note the significant increase in p-P38 in hypoxic microglia. Scale bars a-i -
50μm
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Fig. 35 Western blot analysis showing the protein expression of p-CREB and MKP1 in 
control (C), control with KC7F2 (a HIF-1α inhibitor) (C+K), control with deferoxamine 
(C+D), control +U0126 (an inhibitor for ERK) (C+U), hypoxia (H), Hypoxia + KC7F2 
(H+K), hypoxia + deferoxamine (H+D) and hypoxia + U0126 (H+U) groups of 
microglia. Panel A shows the immunoreactive bands for p-CREB and MKP1 which 
appeared at 43 kDa and 40 kDa respectively. Bar graphs in B, C shows the significant 
changes in their protein levels in response to various treatments. Note the reduction in 
p-CREB in hypoxic microglia when treated with U0126. The significant changes were 
represented as *P < 0.05, **P <0.01 with respect to control microglial group and 
#p<0.05, ##p<0.01 with respect to hypoxic microglia. 
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Fig 36. Protein expression of TNF-α and IL-1β in control (C), control with KC7F2 
(C+K), control with deferoxamine (C+D), control +SB202190 (P38 inhibitor) (C+P), 
control + SP600125 (JNK inhibitor) (C+J), hypoxia (H), Hypoxia + KC7F2 (H+K), 
hypoxia + deferoxamine (H+D), hypoxia +SB202190 (C+P) and hypoxia + SP600125 
(C+J) groups of microglia. Immunoreactive bands for TNF-α and IL-1β is shown in 
panel A and their corresponding bar graphs is shown in B, C. Note the significant 
decrease in TNF-α and IL-1β in hypoxic microglia treated with deferoxamine and 
SB202190. The significant changes were represented as *P < 0.05, **P <0.01 with 
respect to control and #p<0.05, ##p<0.01 with respect to hypoxic group of microglial 
cells.
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Fig 37.  Bar graph in A shows the significant changes in the total iron content in control, 
hypoxic and deferoxamine treated hypoxic oligodendrocyte  cultures. Note the 
significant increase in iron levels in hypoxic oligodendrocytes and the subsequent 
decrease in iron levels when treated with deferoxamine. Significant differences between 
control, hypoxic, and deferoxamine treated groups are expressed as follows: *p<0.05; 
**p<0.01. B: Electron microscopic images of control, hypoxic and 
hypoxia+deferoxamine treated oligodendrocytes showing significant changes in the 
structure of endoplasmic reticulum (ER). Note the dilated ER in hypoxic 
oligodendrocytes. Scale bar -0.2µm. 
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Fig 38.  Western blot in A showing the expression of RyR in PWM of neonatal rats 
sacrificed at 3h, 24h, 3d, 7d and 14d following hypoxic exposure. The immunoreactive 
band for RyR (550 kDa) is shown in panel A. Bar graph in B shows the significant 
changes in the protein expressionof RyR in control, hypoxic PWM. Note the significant 
increase in protein expression of RyR in hypoxic samples. Significant differences 
between control and hypoxic groups are expressed as follows: *p<0.05; **p<0.01. C. 
double immunofluorescence showing the localisation of RyR to CC1 labelled 
oligodendrocytes in PWM of 3d old rat brain. Distribution of  CC1(Ca,d; green), RyR 
(Cb,e; red) and their co-localisation (Cc,f). Note the significant increase in RyR in 
hypoxic PWM. 
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Fig 39.  Western blot in A showing the expression of RyR, Bip, IRE-1α, PERK and p53 
in control, control+deferoxamine, hypoxic and hypoxia+deferoxamine groups of 
oligodendrocyte cultures. The immunoreactive band for RyR (550 kDa), Bip (75 kDa), 
IRE-1α (110 kDa), PERK (125 kDa), p53 (50 kDa) and b-actin (43 kDa)  is shown in 
panel A. Bar graph in B-F are their corrresponding bar graphs showing significant 
changes in their expression levels between various treatment groups. Significant 
differences between the groups are expressed as follows: *p<0.05; **p<0.01 with 
respect to control and #p<0.05, ##p<0.01 with respect to hypoxia 
. 
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Fig 40. Double immunofluorescence showing the localisation of Caspase-3 (cas-3) in 
oligodendrocyte cultures. In response to hypoxic exposure there was increased caspase-
3 labelling in oligodendrocytes when compared to the control cells. Distribution of 
CC1(a,d; green), Cas-3 (b,e; red) and their co-localisation (c,f). Note the significant 
increase in Caspase-3 in hypoxic oligodendrocytes. Scale bars a-f - 50µm. 
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